6zlw › Citations

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2.

Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M, Kratzat H, Hayn M, Mackens-Kiani T, Cheng J, Straub JH, Stürzel CM, Fröhlich T, Berninghausen O, Becker T, Kirchhoff F, Sparrer KMJ, Beckmann R
Science 369 1249-1255 (2020)
Related entries: 6zm7, 6zme, 6zmi, 6zmo, 6zmt, 6zn5, 6zon, 6zp4

Cited: 436 times
EuropePMC logo PMID: 32680882

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. A major virulence factor of SARS-CoVs is the nonstructural protein 1 (Nsp1), which suppresses host gene expression by ribosome association. Here, we show that Nsp1 from SARS-CoV-2 binds to the 40S ribosomal subunit, resulting in shutdown of messenger RNA (mRNA) translation both in vitro and in cells. Structural analysis by cryo-electron microscopy of in vitro-reconstituted Nsp1-40S and various native Nsp1-40S and -80S complexes revealed that the Nsp1 C terminus binds to and obstructs the mRNA entry tunnel. Thereby, Nsp1 effectively blocks retinoic acid-inducible gene I-dependent innate immune responses that would otherwise facilitate clearance of the infection. Thus, the structural characterization of the inhibitory mechanism of Nsp1 may aid structure-based drug design against SARS-CoV-2.

Reviews - 6zlw mentioned but not cited (7)

  1. Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. Front Mol Biosci 7 605236 (2020)
  2. A critical overview of computational approaches employed for COVID-19 drug discovery. Muratov EN, Amaro R, Andrade CH, Brown N, Ekins S, Fourches D, Isayev O, Kozakov D, Medina-Franco JL, Merz KM, Oprea TI, Poroikov V, Schneider G, Todd MH, Varnek A, Winkler DA, Zakharov AV, Cherkasov A, Tropsha A. Chem Soc Rev 50 9121-9151 (2021)
  3. Viral and cellular translation during SARS-CoV-2 infection. Eriani G, Martin F. FEBS Open Bio 12 1584-1601 (2022)
  4. A pocket guide on how to structure SARS-CoV-2 drugs and therapies. Littler DR, MacLachlan BJ, Watson GM, Vivian JP, Gully BS. Biochem Soc Trans 48 2625-2641 (2020)
  5. The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. Fertig TE, Chitoiu L, Terinte-Balcan G, Peteu VE, Marta D, Gherghiceanu M. J Cell Mol Med 26 25-34 (2022)
  6. An Overview of the Crystallized Structures of the SARS-CoV-2. Ionescu MI. Protein J 39 600-618 (2020)
  7. Genetic conservation across SARS-CoV-2 non-structural proteins - Insights into possible targets for treatment of future viral outbreaks. Kandwal S, Fayne D. Virology 581 97-115 (2023)

Articles - 6zlw mentioned but not cited (15)

  1. Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation. Lapointe CP, Grosely R, Johnson AG, Wang J, Fernández IS, Puglisi JD. Proc Natl Acad Sci U S A 118 (2021)
  2. SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets. Alsulami AF, Thomas SE, Jamasb AR, Beaudoin CA, Moghul I, Bannerman B, Copoiu L, Vedithi SC, Torres P, Blundell TL. Brief Bioinform 22 769-780 (2021)
  3. Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family. Wang C, Konecki DM, Marciano DC, Govindarajan H, Williams AM, Wastuwidyaningtyas B, Bourquard T, Katsonis P, Lichtarge O. Bioinformatics btab406 (2021)
  4. Modelling studies reveal the importance of the C-terminal inter motif loop of NSP1 as a promising target site for drug discovery and screening of potential phytochemicals to combat SARS-CoV-2. Prabhu D, Rajamanikandan S, Sureshan M, Jeyakanthan J, Saraboji K. J Mol Graph Model 106 107920 (2021)
  5. Clinically observed deletions in SARS-CoV-2 Nsp1 affect its stability and ability to inhibit translation. Kumar P, Schexnaydre E, Rafie K, Kurata T, Terenin I, Hauryliuk V, Carlson LA. FEBS Lett 596 1203-1213 (2022)
  6. Extended ensemble simulations of a SARS-CoV-2 nsp1-5'-UTR complex. Sakuraba S, Xie Q, Kasahara K, Iwakiri J, Kono H. PLoS Comput Biol 18 e1009804 (2022)
  7. In silico analysis of the aggregation propensity of the SARS-CoV-2 proteome: Insight into possible cellular pathologies. Flores-León M, Lázaro DF, Shvachiy L, Krisko A, Outeiro TF. Biochim Biophys Acta Proteins Proteom 1869 140693 (2021)
  8. All Domains of SARS-CoV-2 nsp1 Determine Translational Shutoff and Cytotoxicity of the Protein. Frolov I, Agback T, Palchevska O, Dominguez F, Lomzov A, Agback P, Frolova EI. J Virol 97 e0186522 (2023)
  9. research-article An evolutionarily conserved strategy for ribosome binding and inhibition by β-coronavirus non-structural protein 1. Maurina SF, O'Sullivan JP, Sharma G, Pineda Rodriguez DC, MacFadden A, Cendali F, Henen MA, Kieft JS, Glasgow A, Steckelberg AL. bioRxiv 2023.06.07.544141 (2023)
  10. Biochemical and HDX Mass Spectral Characterization of the SARS-CoV-2 Nsp1 Protein. Mishra N, Kant R, Leung DW, Gross ML, Amarasinghe GK. Biochemistry 62 1744-1754 (2023)
  11. CoVM2: Molecular Biological Data Integration of SARS-CoV-2 Proteins in a Macro-to-Micro Method. Chen H, Hu X, Hu Y, Zhou J, Chen M. Biomolecules 12 1067 (2022)
  12. Functional and druggability analysis of the SARS-CoV-2 proteome. Cavasotto CN, Lamas MS, Maggini J. Eur J Pharmacol 890 173705 (2021)
  13. research-article Identification of evolutionarily stable sites across the SARS-CoV-2 proteome. Wang C, Konecki DM, Marciano DC, Govindarajan H, Williams AM, Wastuwidyaningtyas B, Bourquard T, Katsonis P, Lichtarge O. Res Sq rs.3.rs-95030 (2020)
  14. Inhibition of translation and immune responses by the virulence factor Nsp1 of SARS-CoV-2. Vann KR, Tencer AH, Kutateladze TG. Signal Transduct Target Ther 5 234 (2020)
  15. Synergistic interactions of repurposed drugs that inhibit Nsp1, a major virulence factor for COVID-19. Kao HT, Orry A, Palfreyman MG, Porton B. Sci Rep 12 10174 (2022)


Reviews citing this publication (169)

  1. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, Weis S, Garcia-Salido A, Kox M, Cavaillon JM, Uhle F, Weigand MA, Flohé SB, Wiersinga WJ, Almansa R, de la Fuente A, Martin-Loeches I, Meisel C, Spinetti T, Schefold JC, Cilloniz C, Torres A, Giamarellos-Bourboulis EJ, Ferrer R, Girardis M, Cossarizza A, Netea MG, van der Poll T, Bermejo-Martín JF, Rubio I. Lancet Respir Med 9 622-642 (2021)
  2. Innate immune sensing of coronavirus and viral evasion strategies. Kasuga Y, Zhu B, Jang KJ, Yoo JS. Exp Mol Med 53 723-736 (2021)
  3. Inflammasome activation at the crux of severe COVID-19. Vora SM, Lieberman J, Wu H. Nat Rev Immunol 21 694-703 (2021)
  4. Translational control of coronaviruses. de Breyne S, Vindry C, Guillin O, Condé L, Mure F, Gruffat H, Chavatte L, Ohlmann T. Nucleic Acids Res 48 12502-12522 (2020)
  5. Type I and III interferon responses in SARS-CoV-2 infection. Kim YM, Shin EC. Exp Mol Med 53 750-760 (2021)
  6. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Ramasamy S, Subbian S. Clin Microbiol Rev 34 e00299-20 (2021)
  7. Evolutionary trajectory of SARS-CoV-2 and emerging variants. Singh J, Pandit P, McArthur AG, Banerjee A, Mossman K. Virol J 18 166 (2021)
  8. SARS-CoV-2 reinfection and implications for vaccine development. Nainu F, Abidin RS, Bahar MA, Frediansyah A, Emran TB, Rabaan AA, Dhama K, Harapan H. Hum Vaccin Immunother 16 3061-3073 (2020)
  9. Interplay between SARS-CoV-2 and the type I interferon response. Sa Ribero M, Jouvenet N, Dreux M, Nisole S. PLoS Pathog 16 e1008737 (2020)
  10. Mechanisms of Coronavirus Nsp1-Mediated Control of Host and Viral Gene Expression. Nakagawa K, Makino S. Cells 10 300 (2021)
  11. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  12. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. J Basic Microbiol 61 180-202 (2021)
  13. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2. Xia H, Shi PY. J Interferon Cytokine Res 40 543-548 (2020)
  14. Coronavirus biology and replication: implications for SARS-CoV-2. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Nat Rev Microbiol 19 155-170 (2021)
  15. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Schönrich G, Raftery MJ, Samstag Y. Adv Biol Regul 77 100741 (2020)
  16. Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. Kamyshnyi O, Matskevych V, Lenchuk T, Strilbytska O, Storey K, Lushchak O. Biomed Pharmacother 144 112230 (2021)
  17. The interface between coronaviruses and host cell RNA biology: Novel potential insights for future therapeutic intervention. Maranon DG, Anderson JR, Maranon AG, Wilusz J. Wiley Interdiscip Rev RNA 11 e1614 (2020)
  18. Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. Banoun H. Nephron 145 392-403 (2021)
  19. Repositioning Vitamin C as a Promising Option to Alleviate Complications associated with COVID-19. Farjana M, Moni A, Sohag AAM, Hasan A, Hannan MA, Hossain MG, Uddin MJ. Infect Chemother 52 461-477 (2020)
  20. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Malone B, Urakova N, Snijder EJ, Campbell EA. Nat Rev Mol Cell Biol 23 21-39 (2022)
  21. Type I interferon: From innate response to treatment for COVID-19. Lin F, Shen K. Pediatr Investig 4 275-280 (2020)
  22. Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis. Ahluwalia P, Ahluwalia M, Vaibhav K, Mondal A, Sahajpal N, Islam S, Fulzele S, Kota V, Dhandapani K, Baban B, Rojiani AM, Kolhe R. EPMA J 11 581-601 (2020)
  23. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL. Mol Cell 79 710-727 (2020)
  24. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. Beyer DK, Forero A. J Mol Biol 434 167265 (2022)
  25. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Motamedi H, Ari MM, Dashtbin S, Fathollahi M, Hossainpour H, Alvandi A, Moradi J, Abiri R. Int Immunopharmacol 96 107763 (2021)
  26. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Nat Rev Nephrol 17 46-64 (2021)
  27. The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. Barrantes FJ. Brain Behav Immun Health 14 100251 (2021)
  28. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. Vashishtha VM, Kumar P. Hum Vaccin Immunother 17 1635-1649 (2021)
  29. Immune evasion of SARS-CoV-2 from interferon antiviral system. Min YQ, Huang M, Sun X, Deng F, Wang H, Ning YJ. Comput Struct Biotechnol J 19 4217-4225 (2021)
  30. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection. Chiale C, Greene TT, Zuniga EI. Immunol Rev 309 12-24 (2022)
  31. Acute Infection of Viral Pathogens and Their Innate Immune Escape. Rai KR, Shrestha P, Yang B, Chen Y, Liu S, Maarouf M, Chen JL. Front Microbiol 12 672026 (2021)
  32. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. Znaidia M, Demeret C, van der Werf S, Komarova AV. Viruses 14 1247 (2022)
  33. I(nsp1)ecting SARS-CoV-2-ribosome interactions. Simeoni M, Cavinato T, Rodriguez D, Gatfield D. Commun Biol 4 715 (2021)
  34. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Harrison AG, Lin T, Wang P. Trends Immunol 41 1100-1115 (2020)
  35. Roles and functions of SARS-CoV-2 proteins in host immune evasion. Rashid F, Xie Z, Suleman M, Shah A, Khan S, Luo S. Front Immunol 13 940756 (2022)
  36. Differential roles of interferons in innate responses to mucosal viral infections. Walker FC, Sridhar PR, Baldridge MT. Trends Immunol 42 1009-1023 (2021)
  37. Overview of SARS-CoV-2 genome-encoded proteins. Bai C, Zhong Q, Gao GF. Sci China Life Sci 65 280-294 (2022)
  38. Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. Liao MT, Wu CC, Wu SV, Lee MC, Hu WC, Tsai KW, Yang CH, Lu CL, Chiu SK, Lu KC. Antioxidants (Basel) 10 1440 (2021)
  39. Innate immunity: the first line of defense against SARS-CoV-2. Diamond MS, Kanneganti TD. Nat Immunol 23 165-176 (2022)
  40. Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. Burtscher J, Cappellano G, Omori A, Koshiba T, Millet GP. iScience 23 101631 (2020)
  41. RNA regulatory mechanisms that control antiviral innate immunity. Gokhale NS, Smith JR, Van Gelder RD, Savan R. Immunol Rev 304 77-96 (2021)
  42. Roles of Type I and III Interferons in COVID-19. Choi H, Shin EC. Yonsei Med J 62 381-390 (2021)
  43. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. Emrani J, Ahmed M, Jeffers-Francis L, Teleha JC, Mowa N, Newman RH, Thomas MD. Int J Biol Macromol 193 1249-1273 (2021)
  44. SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. Low ZY, Zabidi NZ, Yip AJW, Puniyamurti A, Chow VTK, Lal SK. Viruses 14 1991 (2022)
  45. SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. Dumache R, Enache A, Macasoi I, Dehelean CA, Dumitrascu V, Mihailescu A, Popescu R, Vlad D, Vlad CS, Muresan C. Pathogens 11 516 (2022)
  46. Threading the Pieces Together: Integrative Perspective on SARS-CoV-2. Kanakan A, Mishra N, Srinivasa Vasudevan J, Sahni S, Khan A, Sharma S, Pandey R. Pathogens 9 E912 (2020)
  47. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Quarleri J, Delpino MV. Cytokine Growth Factor Rev 58 55-65 (2021)
  48. A little less aggregation a little more replication: Viral manipulation of stress granules. Brownsword MJ, Locker N. Wiley Interdiscip Rev RNA 14 e1741 (2023)
  49. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. Zhou H, Ni WJ, Huang W, Wang Z, Cai M, Sun YC. Front Immunol 13 834942 (2022)
  50. An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies. Das A, Ahmed R, Akhtar S, Begum K, Banu S. Gene Rep 23 101122 (2021)
  51. COVID-19 Mechanisms in the Human Body-What We Know So Far. Kumar A, Narayan RK, Prasoon P, Kumari C, Kaur G, Kumar S, Kulandhasamy M, Sesham K, Pareek V, Faiq MA, Pandey SN, Singh HN, Kant K, Shekhawat PS, Raza K, Kumar S. Front Immunol 12 693938 (2021)
  52. Cardiovascular consequences of viral infections: from COVID to other viral diseases. Schultheiss HP, Baumeier C, Pietsch H, Bock CT, Poller W, Escher F. Cardiovasc Res 117 2610-2623 (2021)
  53. Coronavirus Nsp1: Immune Response Suppression and Protein Expression Inhibition. Yuan S, Balaji S, Lomakin IB, Xiong Y. Front Microbiol 12 752214 (2021)
  54. Host mitochondria: more than an organelle in SARS-CoV-2 infection. Shoraka S, Samarasinghe AE, Ghaemi A, Mohebbi SR. Front Cell Infect Microbiol 13 1228275 (2023)
  55. Molecular Virology of SARS-CoV-2 and Related Coronaviruses. Kung YA, Lee KM, Chiang HJ, Huang SY, Wu CJ, Shih SR. Microbiol Mol Biol Rev 86 e0002621 (2022)
  56. NOD-Like Receptors: Guards of Cellular Homeostasis Perturbation during Infection. Pei G, Dorhoi A. Int J Mol Sci 22 6714 (2021)
  57. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. Higashikuni Y, Liu W, Obana T, Sata M. Int J Mol Sci 22 12081 (2021)
  58. Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. Garcia-Del-Barco D, Risco-Acevedo D, Berlanga-Acosta J, Martos-Benítez FD, Guillén-Nieto G. Front Immunol 12 655528 (2021)
  59. SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. Int J Mol Sci 23 1716 (2022)
  60. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Zhou H, Møhlenberg M, Thakor JC, Tuli HS, Wang P, Assaraf YG, Dhama K, Jiang S. Clin Microbiol Rev 35 e0001422 (2022)
  61. Structural insights into SARS-CoV-2 infection and therapeutics development. Sun G, Xue L, He Q, Zhao Y, Xu W, Wang Z. Stem Cell Res 52 102219 (2021)
  62. The Role of Coronavirus RNA-Processing Enzymes in Innate Immune Evasion. Mandilara G, Koutsi MA, Agelopoulos M, Sourvinos G, Beloukas A, Rampias T. Life (Basel) 11 571 (2021)
  63. Type I interferons and SARS-CoV-2: from cells to organisms. Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL. Curr Opin Immunol 74 172-182 (2022)
  64. An Update on Innate Immune Responses during SARS-CoV-2 Infection. Zhang Y, Chen S, Jin Y, Ji W, Zhang W, Duan G. Viruses 13 2060 (2021)
  65. An overview of human proteins and genes involved in SARS-CoV-2 infection. Jahanafrooz Z, Chen Z, Bao J, Li H, Lipworth L, Guo X. Gene 808 145963 (2022)
  66. Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. Liu Q, Chi S, Dmytruk K, Dmytruk O, Tan S. Viruses 14 1349 (2022)
  67. Covid-19: virology, variants, and vaccines. Young M, Crook H, Scott J, Edison P. BMJ Med 1 e000040 (2022)
  68. Direct mechanisms of SARS-CoV-2-induced cardiomyocyte damage: an update. Yang Y, Wei Z, Xiong C, Qian H. Virol J 19 108 (2022)
  69. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S, Ahmed N, Ahmed N, Ratts R, Raju S, Gallogly M, de Lima M, Sohail MR. Virol J 17 154 (2020)
  70. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. Karki R, Kanneganti TD. J Transl Med 20 542 (2022)
  71. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. Abdalla AE, Xie J, Junaid K, Younas S, Elsaman T, Abosalif KOA, Alameen AAM, Mahjoob MO, Elamir MYM, Ejaz H. Bosn J Basic Med Sci 21 515-527 (2021)
  72. Lessons Learned and Yet-to-Be Learned on the Importance of RNA Structure in SARS-CoV-2 Replication. Bassett M, Salemi M, Rife Magalis B. Microbiol Mol Biol Rev 86 e0005721 (2022)
  73. Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. Sahu U, Biswas D, Singh AK, Khare P. Virusdisease 32 211-219 (2021)
  74. Myeloid dysregulation and therapeutic intervention in COVID-19. Gu R, Mao T, Lu Q, Tianjiao Su T, Wang J. Semin Immunol 55 101524 (2021)
  75. Oral antiviral treatments for COVID-19: opportunities and challenges. Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zarębska-Michaluk D, Rezaei N, Rzymski P. Pharmacol Rep 74 1255-1278 (2022)
  76. Review Devil's tools: SARS-CoV-2 antagonists against innate immunity. Xu D, Biswal M, Neal A, Hai R. Curr Res Virol Sci 2 100013 (2021)
  77. SARS-CoV-2 Virology. Li Y, Li JZ. Infect Dis Clin North Am 36 251-265 (2022)
  78. SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. Evans N, Martinez E, Petrosillo N, Nichols J, Islam E, Pruitt K, Almodovar S. HIV AIDS (Auckl) 13 361-375 (2021)
  79. The space between notes: emerging roles for translationally silent ribosomes. Smith PR, Pandit SC, Loerch S, Campbell ZT. Trends Biochem Sci 47 477-491 (2022)
  80. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19. van de Leemput J, Han Z. Mol Cell Biol 41 e0018521 (2021)
  81. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. Front Immunol 13 801522 (2022)
  82. COVID-19 Biogenesis and Intracellular Transport. Mironov AA, Savin MA, Beznoussenko GV. Int J Mol Sci 24 4523 (2023)
  83. COVID-19 and Psychotic Symptoms: the View from Psychiatric Immunology. Tripathy S, Singh N, Singh A, Kar SK. Curr Behav Neurosci Rep 8 172-178 (2021)
  84. Coronavirus, the King Who Wanted More Than a Crown: From Common to the Highly Pathogenic SARS-CoV-2, Is the Key in the Accessory Genes? Chazal N. Front Microbiol 12 682603 (2021)
  85. Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network. Papanikolaou C, Rapti V, Stellas D, Stefanou DT, Syrigos K, Pavlakis GN, Souliotis VL. Vaccines (Basel) 10 1764 (2022)
  86. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, Madan T, Kishore U. Immunobiology 225 152008 (2020)
  87. Know your enemy and know yourself - the case of SARS-CoV-2 host factors. Lee WS, Yousefi M, Yan B, Yong CL, Ooi YS. Curr Opin Virol 50 159-170 (2021)
  88. Membrane remodeling by SARS-CoV-2 - double-enveloped viral replication. Mohan J, Wollert T. Fac Rev 10 17 (2021)
  89. Oral Polio Vaccine to Protect Against COVID-19: Out of the Box Strategies? Malave Sanchez M, Saleeb P, Kottilil S, Mathur P. Open Forum Infect Dis 8 ofab367 (2021)
  90. Proteomics in the COVID-19 Battlefield: First Semester Check-Up. Grenga L, Armengaud J. Proteomics 21 e2000198 (2021)
  91. Ribosome biogenesis in disease: new players and therapeutic targets. Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, Song YH, Li Y. Signal Transduct Target Ther 8 15 (2023)
  92. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways. Oh SJ, Shin OS. J Microbiol 60 290-299 (2022)
  93. Specialized Ribosomes in Health and Disease. Miller SC, MacDonald CC, Kellogg MK, Karamysheva ZN, Karamyshev AL. Int J Mol Sci 24 6334 (2023)
  94. Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. Wei Y, Shah R. Pharmaceuticals (Basel) 13 (2020)
  95. The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion? Wang Z, Zhou M, Fu Z, Zhao L. Front Immunol 12 693579 (2021)
  96. Transcription factor Nrf2 as a potential therapeutic target for COVID-19. Wang Y, Ma J, Jiang Y. Cell Stress Chaperones 28 11-20 (2023)
  97. Viral evasion of the interferon response at a glance. Zhu J, Chiang C, Gack MU. J Cell Sci 136 jcs260682 (2023)
  98. Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19. Zhang J, Zhao C, Zhao W. Front Immunol 12 633769 (2021)
  99. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Kim DS, Rowland-Jones S, Gea-Mallorquí E. Front Immunol 11 571481 (2020)
  100. A Defective Viral Particle Approach to COVID-19. Kalamvoki M, Norris V. Cells 11 302 (2022)
  101. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  102. Assessing the suitability of long non-coding RNAs as therapeutic targets and biomarkers in SARS-CoV-2 infection. Zhong Y, Ashley CL, Steain M, Ataide SF. Front Mol Biosci 9 975322 (2022)
  103. Bacterial Ribosome Rescue Systems. Kurita D, Himeno H. Microorganisms 10 372 (2022)
  104. Broad-Spectrum Antivirals Derived from Natural Products. Tian WJ, Wang XJ. Viruses 15 1100 (2023)
  105. COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines. Biswas B, Chattopadhyay S, Hazra S, Hansda AK, Goswami R. Inflamm Res 71 377-396 (2022)
  106. COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Xie B, Zhang J, Li Y, Yuan S, Shang Y. Front Immunol 11 607583 (2020)
  107. COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. Chakravarty S. J Proteome Res 20 139-153 (2021)
  108. Coronavirus takeover of host cell translation and intracellular antiviral response: a molecular perspective. Karousis ED, Schubert K, Ban N. EMBO J 43 151-167 (2024)
  109. Development of synthetic antigen vaccines for COVID-19. Viana Invenção MDC, Melo ARDS, de Macêdo LS, da Costa Neves TSP, de Melo CML, Cordeiro MN, de Aragão Batista MV, de Freitas AC. Hum Vaccin Immunother 17 3855-3870 (2021)
  110. Does Covera-19 know 'when to hold 'em or 'when to fold 'em? A translational thought experiment. Griffin GD. Transl Med Commun 6 12 (2021)
  111. Endoplasmic Reticulum Stress in Elderly Patients with COVID-19: Potential of Melatonin Treatment. Yiang GT, Wu CC, Lu CL, Hu WC, Tsai YJ, Huang YM, Su WL, Lu KC. Viruses 15 156 (2023)
  112. Evaluating the Virology and Evolution of Seasonal Human Coronaviruses Associated with the Common Cold in the COVID-19 Era. Harrison CM, Doster JM, Landwehr EH, Kumar NP, White EJ, Beachboard DC, Stobart CC. Microorganisms 11 445 (2023)
  113. Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic? Al Naggar Y, Giesy JP, Abdel-Daim MM, Javed Ansari M, Al-Kahtani SN, Yahya G. Saudi J Biol Sci (2020)
  114. Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications. Singh D, Wasan H, Reeta KH. Free Radic Biol Med 161 263-271 (2020)
  115. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Bienvenu LA, Noonan J, Wang X, Peter K. Cardiovasc Res 116 2197-2206 (2020)
  116. Host and Viral Zinc-Finger Proteins in COVID-19. Esposito S, D'Abrosca G, Antolak A, Pedone PV, Isernia C, Malgieri G. Int J Mol Sci 23 3711 (2022)
  117. How Different Pathologies Are Affected by IFIT Expression. Franco JH, Chattopadhyay S, Pan ZK. Viruses 15 342 (2023)
  118. Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. Li Y, Niu L. Sci Rep 12 16040 (2022)
  119. Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches. Ahmadi S, Bazargan M, Elahi R, Esmaeilzadeh A. Mol Immunol 156 10-19 (2023)
  120. Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic. Li X, Zhang Y, He L, Si J, Qiu S, He Y, Wei J, Wang Z, Xie L, Li Y, Teng T. Int J Biol Sci 18 1865-1877 (2022)
  121. Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. Kheshtchin N, Bakhshi P, Arab S, Nourizadeh M. Int Immunopharmacol 105 108531 (2022)
  122. Improved understanding of biorisk for research involving microbial modification using annotated sequences of concern. Godbold GD, Hewitt FC, Kappell AD, Scholz MB, Agar SL, Treangen TJ, Ternus KL, Sandbrink JB, Koblentz GD. Front Bioeng Biotechnol 11 1124100 (2023)
  123. Innate Immunity Evasion Strategies of Highly Pathogenic Coronaviruses: SARS-CoV, MERS-CoV, and SARS-CoV-2. Li JY, Zhou ZJ, Wang Q, He QN, Zhao MY, Qiu Y, Ge XY. Front Microbiol 12 770656 (2021)
  124. Innate immune evasion strategies of SARS-CoV-2. Minkoff JM, tenOever B. Nat Rev Microbiol 21 178-194 (2023)
  125. Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus. Liu G, Gack MU. Curr Opin Immunol 78 102252 (2022)
  126. Interferon antagonists encoded by SARS-CoV-2 at a glance. Lee JH, Koepke L, Kirchhoff F, Sparrer KMJ. Med Microbiol Immunol (2022)
  127. Interspecies transmission of SARS CoV-2 with special emphasis on viral mutations and ACE-2 receptor homology roles. Hamdy ME, El Deeb AH, Hagag NM, Shahein MA, Alaidi O, Hussein HA. Int J Vet Sci Med 11 55-86 (2023)
  128. Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. Alon R, Sportiello M, Kozlovski S, Kumar A, Reilly EC, Zarbock A, Garbi N, Topham DJ. Nat Rev Immunol 21 49-64 (2021)
  129. Long Covid: where we stand and challenges ahead. Mantovani A, Morrone MC, Patrono C, Santoro MG, Schiaffino S, Remuzzi G, Bussolati G, Covid-19 Commission of the Accademia Nazionale dei Lincei. Cell Death Differ 29 1891-1900 (2022)
  130. Mechanisms contributing to adverse outcomes of COVID-19 in obesity. Sudhakar M, Winfred SB, Meiyazhagan G, Venkatachalam DP. Mol Cell Biochem 477 1155-1193 (2022)
  131. Mechanisms of impairment of interferon production by SARS-CoV-2. Hoang HD, Naeli P, Alain T, Jafarnejad SM. Biochem Soc Trans 51 1047-1056 (2023)
  132. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings. Midha IK, Kumar N, Kumar A, Madan T. Rev Med Virol e2204 (2020)
  133. Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19. Loh D, Reiter RJ. Int J Mol Sci 23 8122 (2022)
  134. Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection. Chen P, Wu M, He Y, Jiang B, He ML. Signal Transduct Target Ther 8 237 (2023)
  135. Minding the message: tactics controlling RNA decay, modification, and translation in virus-infected cells. Burgess HM, Vink EI, Mohr I. Genes Dev 36 108-132 (2022)
  136. Non-Canonical Translation Initiation Mechanisms Employed by Eukaryotic Viral mRNAs. Sorokin II, Vassilenko KS, Terenin IM, Kalinina NO, Agol VI, Dmitriev SE. Biochemistry (Mosc) 86 1060-1094 (2021)
  137. Pathophysiology of stress granules: An emerging link to diseases (Review). Wang J, Gan Y, Cao J, Dong X, Ouyang W. Int J Mol Med 49 44 (2022)
  138. Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus. Tang M, Zhang X, Huang Y, Cheng W, Qu J, Gui S, Li L, Li S. Front Microbiol 13 1093646 (2022)
  139. Phase separation by the SARS-CoV-2 nucleocapsid protein: Consensus and open questions. Cascarina SM, Ross ED. J Biol Chem 298 101677 (2022)
  140. Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines. Li Z, Ma Z, Li Y, Gao S, Xiao S. Microb Pathog 149 104553 (2020)
  141. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. Liu XH, Zhang X, Lu ZH, Zhu YS, Wang T. Biomed Pharmacother 133 111035 (2021)
  142. Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Bakadia BM, He F, Souho T, Lamboni L, Ullah MW, Boni BO, Ahmed AAQ, Mukole BM, Yang G. Biomed Pharmacother 133 111008 (2021)
  143. Replication of the coronavirus genome: A paradox among positive-strand RNA viruses. Grellet E, L'Hôte I, Goulet A, Imbert I. J Biol Chem 298 101923 (2022)
  144. Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. Pozdnyakova V, Weber B, Cheng S, Ebinger JE. Cardiol Clin 40 301-308 (2022)
  145. Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. Pozdnyakova V, Weber B, Cheng S, Ebinger JE. Heart Fail Clin 19 177-184 (2023)
  146. Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. Wei J, Hui A. Life (Basel) 12 57 (2022)
  147. Roadblocks and fast tracks: How RNA binding proteins affect the viral RNA journey in the cell. Girardi E, Pfeffer S, Baumert TF, Majzoub K. Semin Cell Dev Biol (2020)
  148. SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Muñoz-Basagoiti J, Perez-Zsolt D, Carrillo J, Blanco J, Clotet B, Izquierdo-Useros N. Membranes (Basel) 11 (2021)
  149. SARS-CoV-2 Nsp1: Ein kleines Protein blockiert die Immunantwort. Sparrer K, Kirchhoff F. Biospektrum (Heidelb) 27 368-371 (2021)
  150. SARS-CoV-2 and the DNA damage response. Grand RJ. J Gen Virol 104 (2023)
  151. SARS-CoV-2 and the host-immune response. Maison DP, Deng Y, Gerschenson M. Front Immunol 14 1195871 (2023)
  152. SARS-CoV-2 biology and host interactions. Steiner S, Kratzel A, Barut GT, Lang RM, Aguiar Moreira E, Thomann L, Kelly JN, Thiel V. Nat Rev Microbiol (2024)
  153. Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19. Dinda B, Dinda M, Dinda S, Chakraborty M. Eur J Med Chem Rep 6 100079 (2022)
  154. Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. Nakamura T, Isoda N, Sakoda Y, Harashima H. J Control Release 343 361-378 (2022)
  155. Structural biology of SARS-CoV-2: open the door for novel therapies. Yan W, Zheng Y, Zeng X, He B, Cheng W. Signal Transduct Target Ther 7 26 (2022)
  156. Structural insights into SARS-CoV-2 proteins. Arya R, Kumari S, Pandey B, Mistry H, Bihani SC, Das A, Prashar V, Gupta GD, Panicker L, Kumar M. J Mol Biol 433 166725 (2021)
  157. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Wu CR, Yin WC, Jiang Y, Xu HE. Acta Pharmacol Sin (2022)
  158. Targeting SARS-CoV-2 Non-Structural Proteins. Tam D, Lorenzo-Leal AC, Hernández LR, Bach H. Int J Mol Sci 24 13002 (2023)
  159. The Interplay Between Coronavirus and Type I IFN Response. Xue W, Ding C, Qian K, Liao Y. Front Microbiol 12 805472 (2021)
  160. The Role of Viral RNA Degrading Factors in Shutoff of Host Gene Expression. Gaucherand L, Gaglia MM. Annu Rev Virol 9 213-238 (2022)
  161. The immunology and immunotherapy for COVID-19. Liu Y, Zhou X, Liu X, Jiang X. Expert Rev Mol Med 23 e24 (2021)
  162. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Ning Q, Wu D, Wang X, Xi D, Chen T, Chen G, Wang H, Lu H, Wang M, Zhu L, Hu J, Liu T, Ma K, Han M, Luo X. Signal Transduct Target Ther 7 57 (2022)
  163. The molecular basis of translation initiation and its regulation in eukaryotes. Brito Querido J, Díaz-López I, Ramakrishnan V. Nat Rev Mol Cell Biol (2023)
  164. The role of extracellular DNA in COVID-19: Clues from inflamm-aging. Storci G, Bonifazi F, Garagnani P, Olivieri F, Bonafè M. Ageing Res Rev 66 101234 (2021)
  165. Translational Control of COVID-19 and Its Therapeutic Implication. Zhang D, Zhu L, Wang Y, Li P, Gao Y. Front Immunol 13 857490 (2022)
  166. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Tulimilli SV, Dallavalasa S, Basavaraju CG, Kumar Rao V, Chikkahonnaiah P, Madhunapantula SV, Veeranna RP. Vaccines (Basel) 10 1751 (2022)
  167. What do we know about the function of SARS-CoV-2 proteins? Justo Arevalo S, Castillo-Chávez A, Uribe Calampa CS, Zapata Sifuentes D, Huallpa CJ, Landa Bianchi G, Garavito-Salini Casas R, Quiñones Aguilar M, Pineda Chavarría R. Front Immunol 14 1249607 (2023)
  168. When Poly(A) Binding Proteins Meet Viral Infections, Including SARS-CoV-2. Gao J, Tang YD, Hu W, Zheng C. J Virol 96 e0013622 (2022)
  169. [Interaction between SARS-CoV-2 and Host Innate Immunity]. Duan XQ, Xie H, Chen LM. Sichuan Da Xue Xue Bao Yi Xue Ban 53 1-6 (2022)

Articles citing this publication (245)

  1. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Yamada T, Sato S, Sotoyama Y, Orba Y, Sawa H, Yamauchi H, Sasaki M, Takaoka A. Nat Immunol 22 820-828 (2021)
  2. Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Hayn M, Hirschenberger M, Koepke L, Nchioua R, Straub JH, Klute S, Hunszinger V, Zech F, Prelli Bozzo C, Aftab W, Christensen MH, Conzelmann C, Müller JA, Srinivasachar Badarinarayan S, Stürzel CM, Forne I, Stenger S, Conzelmann KK, Münch J, Schmidt FI, Sauter D, Imhof A, Kirchhoff F, Sparrer KMJ. Cell Rep 35 109126 (2021)
  3. SARS-CoV-2 nsp1: Bioinformatics, Potential Structural and Functional Features, and Implications for Drug/Vaccine Designs. Min YQ, Mo Q, Wang J, Deng F, Wang H, Ning YJ. Front Microbiol 11 587317 (2020)
  4. The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation. Tidu A, Janvier A, Schaeffer L, Sosnowski P, Kuhn L, Hammann P, Westhof E, Eriani G, Martin F. RNA rna.078121.120 (2020)
  5. Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions. Flynn RA, Belk JA, Qi Y, Yasumoto Y, Wei J, Alfajaro MM, Shi Q, Mumbach MR, Limaye A, DeWeirdt PC, Schmitz CO, Parker KR, Woo E, Chang HY, Horvath TL, Carette JE, Bertozzi CR, Wilen CB, Satpathy AT. Cell 184 2394-2411.e16 (2021)
  6. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Hsu JC, Laurent-Rolle M, Pawlak JB, Wilen CB, Cresswell P. Proc Natl Acad Sci U S A 118 e2101161118 (2021)
  7. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Gassen NC, Papies J, Bajaj T, Emanuel J, Dethloff F, Chua RL, Trimpert J, Heinemann N, Niemeyer C, Weege F, Hönzke K, Aschman T, Heinz DE, Weckmann K, Ebert T, Zellner A, Lennarz M, Wyler E, Schroeder S, Richter A, Niemeyer D, Hoffmann K, Meyer TF, Heppner FL, Corman VM, Landthaler M, Hocke AC, Morkel M, Osterrieder N, Conrad C, Eils R, Radbruch H, Giavalisco P, Drosten C, Müller MA. Nat Commun 12 3818 (2021)
  8. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Wang W, Zhou Z, Xiao X, Tian Z, Dong X, Wang C, Li L, Ren L, Lei X, Xiang Z, Wang J. Cell Mol Immunol 18 945-953 (2021)
  9. Global analysis of protein-RNA interactions in SARS-CoV-2-infected cells reveals key regulators of infection. Kamel W, Noerenberg M, Cerikan B, Chen H, Järvelin AI, Kammoun M, Lee JY, Shuai N, Garcia-Moreno M, Andrejeva A, Deery MJ, Johnson N, Neufeldt CJ, Cortese M, Knight ML, Lilley KS, Martinez J, Davis I, Bartenschlager R, Mohammed S, Castello A. Mol Cell 81 2851-2867.e7 (2021)
  10. How the coronavirus infects cells - and why Delta is so dangerous. Scudellari M. Nature 595 640-644 (2021)
  11. Structural characterization of nonstructural protein 1 from SARS-CoV-2. Semper C, Watanabe N, Savchenko A. iScience 24 101903 (2021)
  12. The SARS-CoV-2 RNA interactome. Lee S, Lee YS, Choi Y, Son A, Park Y, Lee KM, Kim J, Kim JS, Kim VN. Mol Cell 81 2838-2850.e6 (2021)
  13. Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins. Rui Y, Su J, Shen S, Hu Y, Huang D, Zheng W, Lou M, Shi Y, Wang M, Chen S, Zhao N, Dong Q, Cai Y, Xu R, Zheng S, Yu XF. Signal Transduct Target Ther 6 123 (2021)
  14. Common Genetic Variation in Humans Impacts In Vitro Susceptibility to SARS-CoV-2 Infection. Dobrindt K, Hoagland DA, Seah C, Kassim B, O'Shea CP, Murphy A, Iskhakova M, Fernando MB, Powell SK, Deans PJM, Javidfar B, Peter C, Møller R, Uhl SA, Garcia MF, Kimura M, Iwasawa K, Crary JF, Kotton DN, Takebe T, Huckins LM, tenOever BR, Akbarian S, Brennand KJ. Stem Cell Reports 16 505-518 (2021)
  15. Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity. Lin S, Chen H, Chen Z, Yang F, Ye F, Zheng Y, Yang J, Lin X, Sun H, Wang L, Wen A, Dong H, Xiao Q, Deng D, Cao Y, Lu G. Nucleic Acids Res 49 5382-5392 (2021)
  16. Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. Thacker VV, Sharma K, Dhar N, Mancini GF, Sordet-Dessimoz J, McKinney JD. EMBO Rep 22 e52744 (2021)
  17. SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms. Vazquez C, Swanson SE, Negatu SG, Dittmar M, Miller J, Ramage HR, Cherry S, Jurado KA. PLoS One 16 e0253089 (2021)
  18. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors. Kumar A, Ishida R, Strilets T, Cole J, Lopez-Orozco J, Fayad N, Felix-Lopez A, Elaish M, Evseev D, Magor KE, Mahal LK, Nagata LP, Evans DH, Hobman TC. J Virol 95 e0026621 (2021)
  19. SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction. Deinhardt-Emmer S, Böttcher S, Häring C, Giebeler L, Henke A, Zell R, Jungwirth J, Jordan PM, Werz O, Hornung F, Brandt C, Marquet M, Mosig AS, Pletz MW, Schacke M, Rödel J, Heller R, Nietzsche S, Löffler B, Ehrhardt C. J Virol JVI.00110-21 (2021)
  20. SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3. Fung SY, Siu KL, Lin H, Yeung ML, Jin DY. Int J Biol Sci 17 1547-1554 (2021)
  21. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells. Mellott DM, Tseng CT, Drelich A, Fajtová P, Chenna BC, Kostomiris DH, Hsu J, Zhu J, Taylor ZW, Kocurek KI, Tat V, Katzfuss A, Li L, Giardini MA, Skinner D, Hirata K, Yoon MC, Beck S, Carlin AF, Clark AE, Beretta L, Maneval D, Hook V, Frueh F, Hurst BL, Wang H, Raushel FM, O'Donoghue AJ, de Siqueira-Neto JL, Meek TD, McKerrow JH. ACS Chem Biol 16 642-650 (2021)
  22. RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation. Wu Y, Ma L, Cai S, Zhuang Z, Zhao Z, Jin S, Xie W, Zhou L, Zhang L, Zhao J, Cui J. Signal Transduct Target Ther 6 167 (2021)
  23. SARS-CoV-2 infects human adult donor eyes and hESC-derived ocular epithelium. Eriksen AZ, Møller R, Makovoz B, Uhl SA, tenOever BR, Blenkinsop TA. Cell Stem Cell 28 1205-1220.e7 (2021)
  24. A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2. Singh R, Bhardwaj VK, Das P, Purohit R. Comput Biol Med 135 104555 (2021)
  25. Genes with 5' terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 Nsp1 protein. Rao S, Hoskins I, Tonn T, Garcia PD, Ozadam H, Sarinay Cenik E, Cenik C. RNA 27 1025-1045 (2021)
  26. SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. Nchioua R, Kmiec D, Müller JA, Conzelmann C, Groß R, Swanson CM, Neil SJD, Stenger S, Sauter D, Münch J, Sparrer KMJ, Kirchhoff F. mBio 11 (2020)
  27. Computational search for potential COVID-19 drugs from FDAapproved drugs and small molecules of natural origin identifies several anti-virals and plant products. Sharma A, Tiwari V, Sowdhamini R. J Biosci 45 100 (2020)
  28. Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis. Kehrer T, Cupic A, Ye C, Yildiz S, Bouhaddou M, Crossland NA, Barrall EA, Cohen P, Tseng A, Çağatay T, Rathnasinghe R, Flores D, Jangra S, Alam F, Mena I, Aslam S, Saqi A, Rutkowska M, Ummadi MR, Pisanelli G, Richardson RB, Veit EC, Fabius JM, Soucheray M, Polacco BJ, Ak B, Marin A, Evans MJ, Swaney DL, Gonzalez-Reiche AS, Sordillo EM, van Bakel H, Simon V, Zuliani-Alvarez L, Fontoura BMA, Rosenberg BR, Krogan NJ, Martinez-Sobrido L, García-Sastre A, Miorin L. Cell Host Microbe 31 1668-1684.e12 (2023)
  29. SARS-CoV-2 NSP12 Protein Is Not an Interferon-β Antagonist. Li A, Zhao K, Zhang B, Hua R, Fang Y, Jiang W, Zhang J, Hui L, Zheng Y, Li Y, Zhu C, Wang PH, Peng K, Xia Y. J Virol 95 e0074721 (2021)
  30. The N-terminal domain of SARS-CoV-2 nsp1 plays key roles in suppression of cellular gene expression and preservation of viral gene expression. Mendez AS, Ly M, González-Sánchez AM, Hartenian E, Ingolia NT, Cate JH, Glaunsinger BA. Cell Rep 37 109841 (2021)
  31. A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response. Zhao Y, Sui L, Wu P, Wang W, Wang Z, Yu Y, Hou Z, Tan G, Liu Q, Wang G. Signal Transduct Target Ther 6 331 (2021)
  32. Differences in structure and hibernation mechanism highlight diversification of the microsporidian ribosome. Ehrenbolger K, Jespersen N, Sharma H, Sokolova YY, Tokarev YS, Vossbrinck CR, Barandun J. PLoS Biol 18 e3000958 (2020)
  33. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Frere JJ, Serafini RA, Pryce KD, Zazhytska M, Oishi K, Golynker I, Panis M, Zimering J, Horiuchi S, Hoagland DA, Møller R, Ruiz A, Kodra A, Overdevest JB, Canoll PD, Borczuk AC, Chandar V, Bram Y, Schwartz R, Lomvardas S, Zachariou V, tenOever BR. Sci Transl Med 14 eabq3059 (2022)
  34. Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract. Alfi O, Yakirevitch A, Wald O, Wandel O, Izhar U, Oiknine-Djian E, Nevo Y, Elgavish S, Dagan E, Madgar O, Feinmesser G, Pikarsky E, Bronstein M, Vorontsov O, Jonas W, Ives J, Walter J, Zakay-Rones Z, Oberbaum M, Panet A, Wolf DG. J Virol 95 e0013021 (2021)
  35. Lysine 164 is critical for SARS-CoV-2 Nsp1 inhibition of host gene expression. Shen Z, Zhang G, Yang Y, Li M, Yang S, Peng G. J Gen Virol 102 (2021)
  36. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience. Mary A, Hénaut L, Macq PY, Badoux L, Cappe A, Porée T, Eckes M, Dupont H, Brazier M. Front Pharmacol 11 592543 (2020)
  37. SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney. Francis ME, Goncin U, Kroeker A, Swan C, Ralph R, Lu Y, Etzioni AL, Falzarano D, Gerdts V, Machtaler S, Kindrachuk J, Kelvin AA. PLoS Pathog 17 e1009705 (2021)
  38. SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection. Liou TG, Adler FR, Cahill BC, Cox DR, Cox JE, Grant GJ, Hanson KE, Hartsell SC, Hatton ND, Helms MN, Jensen JL, Kartsonaki C, Li Y, Leung DT, Marvin JE, Middleton EA, Osburn-Staker SM, Packer KA, Shakir SM, Sturrock AB, Tardif KD, Warren KJ, Waddoups LJ, Weaver LJ, Zimmerman E, Paine R. Physiol Rep 9 e14761 (2021)
  39. The SARS-unique domain (SUD) of SARS-CoV and SARS-CoV-2 interacts with human Paip1 to enhance viral RNA translation. Lei J, Ma-Lauer Y, Han Y, Thoms M, Buschauer R, Jores J, Thiel V, Beckmann R, Deng W, Leonhardt H, Hilgenfeld R, von Brunn A. EMBO J 40 e102277 (2021)
  40. A distinct mammalian disome collision interface harbors K63-linked polyubiquitination of uS10 to trigger hRQT-mediated subunit dissociation. Narita M, Denk T, Matsuo Y, Sugiyama T, Kikuguchi C, Ito S, Sato N, Suzuki T, Hashimoto S, Machová I, Tesina P, Beckmann R, Inada T. Nat Commun 13 6411 (2022)
  41. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins. Li Y, Xu Z, Lei Q, Lai DY, Hou H, Jiang HW, Zheng YX, Wang XN, Wu J, Ma ML, Zhang B, Chen H, Yu C, Xue JB, Zhang HN, Qi H, Guo SJ, Zhang Y, Lin X, Yao Z, Sheng H, Sun Z, Wang F, Fan X, Tao SC. Cell Rep 36 109391 (2021)
  42. COVID19 Disease Map, a computational knowledge repository of virus-host interaction mechanisms. Ostaszewski M, Niarakis A, Mazein A, Kuperstein I, Phair R, Orta-Resendiz A, Singh V, Aghamiri SS, Acencio ML, Glaab E, Ruepp A, Fobo G, Montrone C, Brauner B, Frishman G, Monraz Gómez LC, Somers J, Hoch M, Kumar Gupta S, Scheel J, Borlinghaus H, Czauderna T, Schreiber F, Montagud A, Ponce de Leon M, Funahashi A, Hiki Y, Hiroi N, Yamada TG, Dräger A, Renz A, Naveez M, Bocskei Z, Messina F, Börnigen D, Fergusson L, Conti M, Rameil M, Nakonecnij V, Vanhoefer J, Schmiester L, Wang M, Ackerman EE, Shoemaker JE, Zucker J, Oxford K, Teuton J, Kocakaya E, Summak GY, Hanspers K, Kutmon M, Coort S, Eijssen L, Ehrhart F, Rex DAB, Slenter D, Martens M, Pham N, Haw R, Jassal B, Matthews L, Orlic-Milacic M, Senff Ribeiro A, Rothfels K, Shamovsky V, Stephan R, Sevilla C, Varusai T, Ravel JM, Fraser R, Ortseifen V, Marchesi S, Gawron P, Smula E, Heirendt L, Satagopam V, Wu G, Riutta A, Golebiewski M, Owen S, Goble C, Hu X, Overall RW, Maier D, Bauch A, Gyori BM, Bachman JA, Vega C, Grouès V, Vazquez M, Porras P, Licata L, Iannuccelli M, Sacco F, Nesterova A, Yuryev A, de Waard A, Turei D, Luna A, Babur O, Soliman S, Valdeolivas A, Esteban-Medina M, Peña-Chilet M, Rian K, Helikar T, Puniya BL, Modos D, Treveil A, Olbei M, De Meulder B, Ballereau S, Dugourd A, Naldi A, Noël V, Calzone L, Sander C, Demir E, Korcsmaros T, Freeman TC, Augé F, Beckmann JS, Hasenauer J, Wolkenhauer O, Wilighagen EL, Pico AR, Evelo CT, Gillespie ME, Stein LD, Hermjakob H, D'Eustachio P, Saez-Rodriguez J, Dopazo J, Valencia A, Kitano H, Barillot E, Auffray C, Balling R, Schneider R, COVID-19 Disease Map Community. Mol Syst Biol 17 e10387 (2021)
  43. Global and local mutations in Bangladeshi SARS-CoV-2 genomes. Hasan MM, Das R, Rasheduzzaman M, Hussain MH, Muzahid NH, Salauddin A, Rumi MH, Mahbubur Rashid SM, Siddiki AZ, Mannan A. Virus Res 297 198390 (2021)
  44. Large-Scale Recombinant Production of the SARS-CoV-2 Proteome for High-Throughput and Structural Biology Applications. Altincekic N, Korn SM, Qureshi NS, Dujardin M, Ninot-Pedrosa M, Abele R, Abi Saad MJ, Alfano C, Almeida FCL, Alshamleh I, de Amorim GC, Anderson TK, Anobom CD, Anorma C, Bains JK, Bax A, Blackledge M, Blechar J, Böckmann A, Brigandat L, Bula A, Bütikofer M, Camacho-Zarco AR, Carlomagno T, Caruso IP, Ceylan B, Chaikuad A, Chu F, Cole L, Crosby MG, de Jesus V, Dhamotharan K, Felli IC, Ferner J, Fleischmann Y, Fogeron ML, Fourkiotis NK, Fuks C, Fürtig B, Gallo A, Gande SL, Gerez JA, Ghosh D, Gomes-Neto F, Gorbatyuk O, Guseva S, Hacker C, Häfner S, Hao B, Hargittay B, Henzler-Wildman K, Hoch JC, Hohmann KF, Hutchison MT, Jaudzems K, Jović K, Kaderli J, Kalniņš G, Kaņepe I, Kirchdoerfer RN, Kirkpatrick J, Knapp S, Krishnathas R, Kutz F, Zur Lage S, Lambertz R, Lang A, Laurents D, Lecoq L, Linhard V, Löhr F, Malki A, Bessa LM, Martin RW, Matzel T, Maurin D, McNutt SW, Mebus-Antunes NC, Meier BH, Meiser N, Mompeán M, Monaca E, Montserret R, Mariño Perez L, Moser C, Muhle-Goll C, Neves-Martins TC, Ni X, Norton-Baker B, Pierattelli R, Pontoriero L, Pustovalova Y, Ohlenschläger O, Orts J, Da Poian AT, Pyper DJ, Richter C, Riek R, Rienstra CM, Robertson A, Pinheiro AS, Sabbatella R, Salvi N, Saxena K, Schulte L, Schiavina M, Schwalbe H, Silber M, Almeida MDS, Sprague-Piercy MA, Spyroulias GA, Sreeramulu S, Tants JN, Tārs K, Torres F, Töws S, Treviño MÁ, Trucks S, Tsika AC, Varga K, Wang Y, Weber ME, Weigand JE, Wiedemann C, Wirmer-Bartoschek J, Wirtz Martin MA, Zehnder J, Hengesbach M, Schlundt A. Front Mol Biosci 8 653148 (2021)
  45. Research Support, Non-U.S. Gov't Molecular mechanisms of Na,K-ATPase dysregulation driving alveolar epithelial barrier failure in severe COVID-19. Kryvenko V, Vadász I. Am J Physiol Lung Cell Mol Physiol 320 L1186-L1193 (2021)
  46. SARS-CoV-2 NSP1 C-terminal (residues 131-180) is an intrinsically disordered region in isolation. Kumar A, Kumar A, Kumar P, Garg N, Giri R. Curr Res Virol Sci 2 100007 (2021)
  47. Interactomes of SARS-CoV-2 and human coronaviruses reveal host factors potentially affecting pathogenesis. Chen Z, Wang C, Feng X, Nie L, Tang M, Zhang H, Xiong Y, Swisher SK, Srivastava M, Chen J. EMBO J 40 e107776 (2021)
  48. Replication and single-cycle delivery of SARS-CoV-2 replicons. Ricardo-Lax I, Luna JM, Thao TTN, Le Pen J, Yu Y, Hoffmann HH, Schneider WM, Razooky BS, Fernandez-Martinez J, Schmidt F, Weisblum Y, Trüeb BS, Berenguer Veiga I, Schmied K, Ebert N, Michailidis E, Peace A, Sánchez-Rivera FJ, Lowe SW, Rout MP, Hatziioannou T, Bieniasz PD, Poirier JT, MacDonald MR, Thiel V, Rice CM. Science 374 1099-1106 (2021)
  49. SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. Shemesh M, Aktepe TE, Deerain JM, McAuley JL, Audsley MD, David CT, Purcell DFJ, Urin V, Hartmann R, Moseley GW, Mackenzie JM, Schreiber G, Harari D. PLoS Pathog 17 e1009800 (2021)
  50. The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins. Jaroszewski L, Iyer M, Alisoltani A, Sedova M, Godzik A. PLoS Comput Biol 17 e1009147 (2021)
  51. Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. Armstrong LA, Lange SM, Dee Cesare V, Matthews SP, Nirujogi RS, Cole I, Hope A, Cunningham F, Toth R, Mukherjee R, Bojkova D, Gruber F, Gray D, Wyatt PG, Cinatl J, Dikic I, Davies P, Kulathu Y. PLoS One 16 e0253364 (2021)
  52. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Hatton CF, Botting RA, Dueñas ME, Haq IJ, Verdon B, Thompson BJ, Spegarova JS, Gothe F, Stephenson E, Gardner AI, Murphy S, Scott J, Garnett JP, Carrie S, Powell J, Khan CMA, Huang L, Hussain R, Coxhead J, Davey T, Simpson AJ, Haniffa M, Hambleton S, Brodlie M, Ward C, Trost M, Reynolds G, Duncan CJA. Nat Commun 12 7092 (2021)
  53. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ, Barr RG, Bleecker ER, Bowler RP, Comellas AP, Cooper CB, Couper DJ, Criner GJ, Curtis JL, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Krishnan JA, Martinez FJ, McDonald MN, Meyers DA, Paine R, Peters SP, Castro M, Denlinger LC, Erzurum SC, Fahy JV, Israel E, Jarjour NN, Levy BD, Li X, Moore WC, Wenzel SE, Zein J, NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS), NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Langelier C, Woodruff PG, Lappalainen T, Christenson SA. Genome Med 13 66 (2021)
  54. One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms. Rank A, Tzortzini A, Kling E, Schmid C, Claus R, Löll E, Burger R, Römmele C, Dhillon C, Müller K, Girl P, Hoffmann R, Grützner S, Dennehy KM. J Clin Med 10 3305 (2021)
  55. Positive selection as a key player for SARS-CoV-2 pathogenicity: Insights into ORF1ab, S and E genes. Emam M, Oweda M, Antunes A, El-Hadidi M. Virus Res 302 198472 (2021)
  56. SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. Pawlica P, Yario TA, White S, Wang J, Moss WN, Hui P, Vinetz JM, Steitz JA. Proc Natl Acad Sci U S A 118 e2116668118 (2021)
  57. The final step of 40S ribosomal subunit maturation is controlled by a dual key lock. Plassart L, Shayan R, Montellese C, Rinaldi D, Larburu N, Pichereaux C, Froment C, Lebaron S, O'Donohue MF, Kutay U, Marcoux J, Gleizes PE, Plisson-Chastang C. Elife 10 e61254 (2021)
  58. Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection. Yang B, Fan J, Huang J, Guo E, Fu Y, Liu S, Xiao R, Liu C, Lu F, Qin T, He C, Wang Z, Qin X, Hu D, You L, Li X, Wang T, Wu P, Chen G, Zhou J, Li K, Sun C. Nat Commun 12 3501 (2021)
  59. Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1. Benedetti F, Snyder GA, Giovanetti M, Angeletti S, Gallo RC, Ciccozzi M, Zella D. J Transl Med 18 329 (2020)
  60. Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. Pucci F, Rooman M. Viruses 13 935 (2021)
  61. Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of three proteins from SARS-CoV-2. Slavin M, Zamel J, Zohar K, Eliyahu T, Braitbard M, Brielle E, Baraz L, Stolovich-Rain M, Friedman A, Wolf DG, Rouvinski A, Linial M, Schneidman-Duhovny D, Kalisman N. Proc Natl Acad Sci U S A 118 e2103554118 (2021)
  62. ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Karki R, Lee S, Mall R, Pandian N, Wang Y, Sharma BR, Malireddi RS, Yang D, Trifkovic S, Steele JA, Connelly JP, Vishwanath G, Sasikala M, Reddy DN, Vogel P, Pruett-Miller SM, Webby R, Jonsson CB, Kanneganti TD. Sci Immunol 7 eabo6294 (2022)
  63. Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics. Rampogu S, Lee G, Kulkarni AM, Kim D, Yoon S, Kim MO, Lee KW. ChemistryOpen 10 593-599 (2021)
  64. Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Cheng L, Zhang X, Chen Y, Wang D, Zhang D, Yan S, Wang H, Xiao M, Liang T, Li H, Xu M, Hou X, Dai J, Wu X, Li M, Lu M, Wu D, Tian R, Zhao J, Zhang Y, Cao W, Wang J, Yan X, Zhou X, Liu Z, Xu Y, He F, Li Y, Yu X, Zhang S. Signal Transduct Target Ther 6 304 (2021)
  65. EDF1 coordinates cellular responses to ribosome collisions. Sinha NK, Ordureau A, Best K, Saba JA, Zinshteyn B, Sundaramoorthy E, Fulzele A, Garshott DM, Denk T, Thoms M, Paulo JA, Harper JW, Bennett EJ, Beckmann R, Green R. Elife 9 (2020)
  66. Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. Troyano-Hernáez P, Reinosa R, Holguín Á. Int J Mol Sci 23 6394 (2022)
  67. Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype. Trombetta AC, Farias GB, Gomes AMC, Godinho-Santos A, Rosmaninho P, Conceição CM, Laia J, Santos DF, Almeida ARM, Mota C, Gomes A, Serrano M, Veldhoen M, Sousa AE, Fernandes SM. Front Immunol 12 691725 (2021)
  68. Structural Basis and Function of the N Terminus of SARS-CoV-2 Nonstructural Protein 1. Zhao K, Ke Z, Hu H, Liu Y, Li A, Hua R, Guo F, Xiao J, Zhang Y, Duan L, Yan XF, Gao YG, Liu B, Xia Y, Li Y. Microbiol Spectr 9 e0016921 (2021)
  69. Structural insights into the activity regulation of full-length non-structural protein 1 from SARS-CoV-2. Wang Y, Kirkpatrick J, Lage SZ, Carlomagno T. Structure 31 128-137.e5 (2023)
  70. 1H, 13C and 15N resonance assignment of the SARS-CoV-2 full-length nsp1 protein and its mutants reveals its unique secondary structure features in solution. Agback T, Dominguez F, Frolov I, Frolova EI, Agback P. PLoS One 16 e0251834 (2021)
  71. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. Yang J, Lin S, Sun H, Chen Z, Yang F, Lin X, Guo L, Wang L, Wen A, Zhang X, Dai Y, He B, Cao Y, Dong H, Liu X, Chen B, Li J, Zhao Q, Lu G. Front Immunol 13 820336 (2022)
  72. A Structurally Conserved RNA Element within SARS-CoV-2 ORF1a RNA and S mRNA Regulates Translation in Response to Viral S Protein-Induced Signaling in Human Lung Cells. Basu A, Penumutchu S, Nguyen K, Mbonye U, Tolbert BS, Karn J, Komar AA, Mazumder B. J Virol 96 e0167821 (2022)
  73. All hands on deck: SARS-CoV-2 proteins that block early anti-viral interferon responses. Setaro AC, Gaglia MM. Curr Res Virol Sci 2 100015 (2021)
  74. Charcot-Marie-Tooth mutation in glycyl-tRNA synthetase stalls ribosomes in a pre-accommodation state and activates integrated stress response. Mendonsa S, von Kuegelgen N, Bujanic L, Chekulaeva M. Nucleic Acids Res 49 10007-10017 (2021)
  75. Comparative analysis of non structural protein 1 of SARS-CoV2 with SARS-CoV1 and MERS-CoV: An in silico study. Chaudhuri A. J Mol Struct 1243 130854 (2021)
  76. Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. Rando HM, MacLean AL, Lee AJ, Lordan R, Ray S, Bansal V, Skelly AN, Sell E, Dziak JJ, Shinholster L, D'Agostino McGowan L, Ben Guebila M, Wellhausen N, Knyazev S, Boca SM, Capone S, Qi Y, Park Y, Mai D, Sun Y, Boerckel JD, Brueffer C, Byrd JB, Kamil JP, Wang J, Velazquez R, Szeto GL, Barton JP, Goel RR, Mangul S, Lubiana T, COVID-19 Review Consortium Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen,, Gitter A, Greene CS. mSystems 6 e0009521 (2021)
  77. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Painter MM, Johnston TS, Lundgreen KA, Santos JJS, Qin JS, Goel RR, Apostolidis SA, Mathew D, Fulmer B, Williams JC, McKeague ML, Pattekar A, Goode A, Nasta S, Baxter AE, Giles JR, Skelly AN, Felley LE, McLaughlin M, Weaver J, Penn Medicine BioBank, Kuthuru O, Dougherty J, Adamski S, Long S, Kee M, Clendenin C, da Silva Antunes R, Grifoni A, Weiskopf D, Sette A, Huang AC, Rader DJ, Hensley SE, Bates P, Greenplate AR, Wherry EJ. Nat Immunol 24 1711-1724 (2023)
  78. SARS CoV-2 Nucleoprotein Enhances the Infectivity of Lentiviral Spike Particles. Mishra T, Sreepadmanabh M, Ramdas P, Sahu AK, Kumar A, Chande A. Front Cell Infect Microbiol 11 663688 (2021)
  79. Structural and Drug Screening Analysis of the Non-structural Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Virus Extracted From Indian Coronavirus Disease 2019 Patients. Biswas N, Kumar K, Mallick P, Das S, Kamal IM, Bose S, Choudhury A, Chakrabarti S. Front Genet 12 626642 (2021)
  80. The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. Puray-Chavez M, Lee N, Tenneti K, Wang Y, Vuong HR, Liu Y, Horani A, Huang T, Gunsten SP, Case JB, Yang W, Diamond MS, Brody SL, Dougherty J, Kutluay SB. mBio 13 e0081522 (2022)
  81. The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation. Meyers JM, Ramanathan M, Shanderson RL, Beck A, Donohue L, Ferguson I, Guo MG, Rao DS, Miao W, Reynolds D, Yang X, Zhao Y, Yang YY, Blish C, Wang Y, Khavari PA. PLoS Pathog 17 e1009412 (2021)
  82. Uncertainty around the Long-Term Implications of COVID-19. Desforges M, Gurdasani D, Hamdy A, Leonardi AJ. Pathogens 10 1267 (2021)
  83. 1H, 13C, and 15N backbone chemical-shift assignments of SARS-CoV-2 non-structural protein 1 (leader protein). Wang Y, Kirkpatrick J, Zur Lage S, Korn SM, Neißner K, Schwalbe H, Schlundt A, Carlomagno T. Biomol NMR Assign 15 287-295 (2021)
  84. A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia. Zhou F, Aroua N, Liu Y, Rohde C, Cheng J, Wirth AK, Fijalkowska D, Göllner S, Lotze M, Yun H, Yu X, Pabst C, Sauer T, Oellerich T, Serve H, Röllig C, Bornhäuser M, Thiede C, Baldus C, Frye M, Raffel S, Krijgsveld J, Jeremias I, Beckmann R, Trumpp A, Müller-Tidow C. Cancer Discov 13 332-347 (2023)
  85. Letter COVID-19 therapies: do we see substantial progress? Matusewicz L, Golec M, Czogalla A, Kuliczkowski K, Konka A, Zembala-John J, Sikorski AF. Cell Mol Biol Lett 27 42 (2022)
  86. Characterisation of the blood RNA host response underpinning severity in COVID-19 patients. Jackson H, Rivero Calle I, Broderick C, Habgood-Coote D, D'Souza G, Nichols S, Vito O, Gómez-Rial J, Rivero-Velasco C, Rodríguez-Núñez N, Barbeito-Castiñeiras G, Pérez-Freixo H, Barreiro-de Acosta M, Cunnington AJ, Herberg JA, Wright VJ, Gómez-Carballa A, Salas A, Levin M, Martinon-Torres F, Kaforou M, PERFORM consortium, GEN-COVID (www.gencovid.eu) study group. Sci Rep 12 12216 (2022)
  87. Coronaviruses: Troubling Crown of the Animal Kingdom. Gozalo AS, Clark TS, Kurtz DM. Comp Med 73 6-44 (2023)
  88. Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV-2 replication. Jiang Y, Tong K, Yao R, Zhou Y, Lin H, Du L, Jin Y, Cao L, Tan J, Zhang XD, Guo D, Pan JA, Peng X. Cell Biosci 11 140 (2021)
  89. Micronucleus production, activation of DNA damage response and cGAS-STING signaling in syncytia induced by SARS-CoV-2 infection. Ren H, Ma C, Peng H, Zhang B, Zhou L, Su Y, Gao X, Huang H. Biol Direct 16 20 (2021)
  90. Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation. Dolliver SM, Kleer M, Bui-Marinos MP, Ying S, Corcoran JA, Khaperskyy DA. PLoS Pathog 18 e1011041 (2022)
  91. RHAMNETIN IS A BETTER INHIBITOR OF SARS-COV-2 2'-O-METHYLTRANSFERASE THAN DOLUTEGRAVIR: A COMPUTATIONAL PREDICTION. Rowaiye AB, Oli AN, Onuh OA, Emeter NW, Bur D, Obideyi OA, Dayisi OC, Akpa JN, Birah L, Omaka EE, Iseghohi FO, Otitoju AP, Uzor PF, Okoyeh JN. Afr J Infect Dis 16 80-96 (2022)
  92. RNA-Binding Proteins at the Host-Pathogen Interface Targeting Viral Regulatory Elements. Embarc-Buh A, Francisco-Velilla R, Martinez-Salas E. Viruses 13 952 (2021)
  93. Letter Replication of SARS-CoV-2 in adipose tissue determines organ and systemic lipid metabolism in hamsters and humans. Zickler M, Stanelle-Bertram S, Ehret S, Heinrich F, Lange P, Schaumburg B, Kouassi NM, Beck S, Jaeckstein MY, Mann O, Krasemann S, Schroeder M, Jarczak D, Nierhaus A, Kluge S, Peschka M, Schlüter H, Renné T, Pueschel K, Kloetgen A, Scheja L, Ondruschka B, Heeren J, Gabriel G. Cell Metab 34 1-2 (2022)
  94. SARS-CoV-2 NSP1 induces mRNA cleavages on the ribosome. Tardivat Y, Sosnowski P, Tidu A, Westhof E, Eriani G, Martin F. Nucleic Acids Res 51 8677-8690 (2023)
  95. SARS-CoV-2 genetic diversity in Venezuela: Predominance of D614G variants and analysis of one outbreak. Loureiro CL, Jaspe RC, D Angelo P, Zambrano JL, Rodriguez L, Alarcon V, Delgado M, Aguilar M, Garzaro D, Rangel HR, Pujol FH. PLoS One 16 e0247196 (2021)
  96. Structural phylogenetic analysis reveals lineage-specific RNA repetitive structural motifs in all coronaviruses and associated variations in SARS-CoV-2. Chen SC, Olsthoorn RCL, Yu CH. Virus Evol 7 veab021 (2021)
  97. Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion. Vora SM, Fontana P, Mao T, Leger V, Zhang Y, Fu TM, Lieberman J, Gehrke L, Shi M, Wang L, Iwasaki A, Wu H. Proc Natl Acad Sci U S A 119 e2117198119 (2022)
  98. The nucleoplasmic phase of pre-40S formation prior to nuclear export. Cheng J, Lau B, Thoms M, Ameismeier M, Berninghausen O, Hurt E, Beckmann R. Nucleic Acids Res 50 11924-11937 (2022)
  99. The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2. Alturaiki W, Mubarak A, Al Jurayyan A, Hemida MG. Hum Vaccin Immunother 17 3297-3309 (2021)
  100. Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo. Ouyang W, Xie T, Fang H, Gao C, Stantchev T, Clouse KA, Yuan K, Ju T, Frucht DM. Int J Mol Sci 22 7540 (2021)
  101. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Zhang S, Huang W, Ren L, Ju X, Gong M, Rao J, Sun L, Li P, Ding Q, Wang J, Zhang QC. Cell Res 32 9-23 (2022)
  102. CryoREAD: de novo structure modeling for nucleic acids in cryo-EM maps using deep learning. Wang X, Terashi G, Kihara D. Nat Methods 20 1739-1747 (2023)
  103. Diagnosing COVID-19 in human sera with detected immunoglobulins IgM and IgG by means of Raman spectroscopy. Goulart ACC, Zângaro RA, Carvalho HC, Silveira L. J Raman Spectrosc (2021)
  104. Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1. Stölting H, Baillon L, Frise R, Bonner K, Hewitt RJ, Molyneaux PL, Gore ML, Breathing Together Consortium, Barclay WS, Saglani S, Lloyd CM. Mucosal Immunol 15 952-963 (2022)
  105. Dynamic association of human Ebp1 with the ribosome. Bhaskar V, Desogus J, Graff-Meyer A, Schenk AD, Cavadini S, Chao JA. RNA 27 411-419 (2021)
  106. Emerging Mutations in Nsp1 of SARS-CoV-2 and Their Effect on the Structural Stability. Mou K, Mukhtar F, Khan MT, Darwish DB, Peng S, Muhammad S, Al-Sehemi AG, Wei DQ. Pathogens 10 1285 (2021)
  107. Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection In Vitro, despite Eliciting a Prolonged Antiviral Response. Gamage AM, Tan KS, Chan WOY, Lew ZZR, Liu J, Tan CW, Rajagopalan D, Lin QXX, Tan LM, Venkatesh PN, Ong YK, Thong M, Lin RTP, Prabhakar S, Wang Y, Wang LF. mBio e0343621 (2022)
  108. Identifying cysteine residues susceptible to oxidation by photoactivatable atomic oxygen precursors using a proteome-wide analysis. Isor A, Chartier BV, Abo M, Currens ER, Weerapana E, McCulla RD. RSC Chem Biol 2 577-591 (2021)
  109. Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins. Zhang F, Zang TM, Stevenson EM, Lei X, Copertino DC, Mota TM, Boucau J, Garcia-Beltran WF, Jones RB, Bieniasz PD. Proc Natl Acad Sci U S A 119 e2209042119 (2022)
  110. Innate immunology in COVID-19-a living review. Part I: viral entry, sensing and evasion. Coveney C, Tellier M, Lu F, Maleki-Toyserkani S, Jones R, Bart VMT, Pring E, Alrubayyi A, Richter FC, Scourfield DO, Rehwinkel J, Rodrigues PRS, Davies LC, Gea-Mallorquí E, Oxford-Cardiff COVID19 Literature Consortium. Oxf Open Immunol 1 iqaa004 (2020)
  111. Integrative vectors for regulated expression of SARS-CoV-2 proteins implicated in RNA metabolism. Bresson S, Robertson N, Sani E, Turowski TW, Shchepachev V, Kompauerova M, Spanos C, Helwak A, Tollervey D. Wellcome Open Res 5 261 (2020)
  112. Is haem the real target of COVID-19? Rapozzi V, Juarranz A, Habib A, Ihan A, Strgar R. Photodiagnosis Photodyn Ther 35 102381 (2021)
  113. Lipin-2 regulates the antiviral and anti-inflammatory responses to interferon. de Pablo N, Meana C, Martínez-García J, Martínez-Vicente P, Albert M, Guerra S, Angulo A, Balsinde J, Balboa MA. EMBO Rep 24 e57238 (2023)
  114. Mutations in Porcine Epidemic Diarrhea Virus nsp1 Cause Increased Viral Sensitivity to Host Interferon Responses and Attenuation In Vivo. Niu X, Kong F, Xu J, Liu M, Wang Q. J Virol 96 e0046922 (2022)
  115. Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA. Yuan S, Peng L, Park JJ, Hu Y, Devarkar SC, Dong MB, Shen Q, Wu S, Chen S, Lomakin IB, Xiong Y. Mol Cell 80 1055-1066.e6 (2020)
  116. Nsp1 of SARS-CoV-2 stimulates host translation termination. Shuvalov A, Shuvalova E, Biziaev N, Sokolova E, Evmenov K, Pustogarov N, Arnautova A, Matrosova V, Egorova T, Alkalaeva E. RNA Biol 18 804-817 (2021)
  117. Nsp16 shields SARS-CoV-2 from efficient MDA5 sensing and IFIT1-mediated restriction. Russ A, Wittmann S, Tsukamoto Y, Herrmann A, Deutschmann J, Lagisquet J, Ensser A, Kato H, Gramberg T. EMBO Rep 23 e55648 (2022)
  118. Parsing the role of NSP1 in SARS-CoV-2 infection. Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N. Cell Rep 39 110954 (2022)
  119. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Jiang Y, Yin W, Xu HE. Biochem Biophys Res Commun 538 47-53 (2021)
  120. Ratchet, swivel, tilt and roll: a complete description of subunit rotation in the ribosome. Hassan A, Byju S, Freitas FC, Roc C, Pender N, Nguyen K, Kimbrough EM, Mattingly JM, Gonzalez RL, de Oliveira RJ, Dunham CM, Whitford PC. Nucleic Acids Res 51 919-934 (2023)
  121. Revealing druggable cryptic pockets in the Nsp1 of SARS-CoV-2 and other β-coronaviruses by simulations and crystallography. Borsatto A, Akkad O, Galdadas I, Ma S, Damfo S, Haider S, Kozielski F, Estarellas C, Gervasio FL. Elife 11 e81167 (2022)
  122. SARS-CoV-2 Codon Usage Bias Downregulates Host Expressed Genes With Similar Codon Usage. Alonso AM, Diambra L. Front Cell Dev Biol 8 831 (2020)
  123. SARS-CoV-2 nonstructural protein 6 triggers endoplasmic reticulum stress-induced autophagy to degrade STING1. Jiao P, Fan W, Ma X, Lin R, Zhao Y, Li Y, Zhang H, Jia X, Bi Y, Feng X, Li M, Liu W, Zhang K, Sun L. Autophagy 19 3113-3131 (2023)
  124. SARS-CoV-2-encoded inhibitors of human LINE-1 retrotransposition. Li Y, Yang J, Shen S, Wang W, Liu N, Guo H, Wei W. J Med Virol 95 e28135 (2023)
  125. SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages. Lu L, Yu S, Liu M, Li Y, Lei Q, Lin M, Lai D, Guo S, Jiang H, Hou H, Zheng Y, Wang X, Ma M, Zhang B, Chen H, Xue J, Zhang H, Qi H, Sun Z, Wang F, Fan X, Xu Z. Acta Biochim Biophys Sin (Shanghai) 54 556-564 (2022)
  126. Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity. Si L, Bai H, Oh CY, Jiang A, Hong F, Zhang T, Ye Y, Jordan TX, Logue J, McGrath M, Belgur C, Calderon K, Nurani A, Cao W, Carlson KE, Prantil-Baun R, Gygi SP, Yang D, Jonsson CB, tenOever BR, Frieman M, Ingber DE. Mol Ther Nucleic Acids 29 923-940 (2022)
  127. Structural basis for the interaction of SARS-CoV-2 virulence factor nsp1 with DNA polymerase α-primase. Kilkenny ML, Veale CE, Guppy A, Hardwick SW, Chirgadze DY, Rzechorzek NJ, Maman JD, Pellegrini L. Protein Sci 31 333-344 (2022)
  128. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Osipiuk J, Azizi SA, Dvorkin S, Endres M, Jedrzejczak R, Jones KA, Kang S, Kathayat RS, Kim Y, Lisnyak VG, Maki SL, Nicolaescu V, Taylor CA, Tesar C, Zhang YA, Zhou Z, Randall G, Michalska K, Snyder SA, Dickinson BC, Joachimiak A. Nat Commun 12 743 (2021)
  129. TMBIM6, a potential virus target protein identified by integrated multiomics data analysis in SARS-CoV-2-infected host cells. Han Q, Wang J, Luo H, Li L, Lu X, Liu A, Deng Y, Jiang Y. Aging (Albany NY) 13 9160-9185 (2021)
  130. The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression. Bujanic L, Shevchuk O, von Kügelgen N, Kalinina A, Ludwik K, Koppstein D, Zerna N, Sickmann A, Chekulaeva M. RNA 28 766-779 (2022)
  131. Two Ligand-Binding Sites on SARS-CoV-2 Non-Structural Protein 1 Revealed by Fragment-Based X-ray Screening. Ma S, Damfo S, Lou J, Pinotsis N, Bowler MW, Haider S, Kozielski F. Int J Mol Sci 23 12448 (2022)
  132. eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content. Duan H, Zhang S, Zarai Y, Öllinger R, Wu Y, Sun L, Hu C, He Y, Tian G, Rad R, Kong X, Cheng Y, Tuller T, Wolf DA. EMBO J 42 e112362 (2023)
  133. Brucella activates the host RIDD pathway to subvert BLOS1-directed immune defense. Wells KM, He K, Pandey A, Cabello A, Zhang D, Yang J, Gomez G, Liu Y, Chang H, Li X, Zhang H, Feng X, da Costa LF, Metz R, Johnson CD, Martin CL, Skrobarczyk J, Berghman LR, Patrick KL, Leibowitz J, Ficht A, Sze SH, Song J, Qian X, Qin QM, Ficht TA, de Figueiredo P. Elife 11 e73625 (2022)
  134. A resource of human coronavirus protein-coding sequences in a flexible, multipurpose Gateway Entry clone collection. Weller B, Lin CW, Pogoutse O, Sauer M, Marin-de la Rosa N, Strobel A, Young V, Knapp JJ, Rayhan A, Falter C, Kim DK, Roth FP, Falter-Braun P. G3 (Bethesda) 13 jkad105 (2023)
  135. Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, Youssef A, Alysandratos KD, Padhorny D, Ojha S, Mora-Martin A, Kretov D, Ash PEA, Verma M, Zhao J, Patten JJ, Villacorta-Martin C, Bolzan D, Perea-Resa C, Bullitt E, Hinds A, Tilston-Lunel A, Varelas X, Farhangmehr S, Braunschweig U, Kwan JH, McComb M, Basu A, Saeed M, Perissi V, Burks EJ, Layne MD, Connor JH, Davey R, Cheng JX, Wolozin BL, Blencowe BJ, Wuchty S, Lyons SM, Kozakov D, Cifuentes D, Blower M, Kotton DN, Wilson AA, Mühlberger E, Emili A. Mol Cell 80 1104-1122.e9 (2020)
  136. Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5. Imbiakha B, Ezzatpour S, Buchholz DW, Sahler J, Ye C, Olarte-Castillo XA, Zou A, Kwas C, O'Hare K, Choi A, Adeleke RA, Khomandiak S, Goodman L, Jager MC, Whittaker GR, Martinez-Sobrido L, August A, Aguilar HC. Sci Adv 9 eadj1736 (2023)
  137. An Evolutionarily Conserved Strategy for Ribosome Binding and Host Translation Inhibition by β-coronavirus Non-structural Protein 1. Maurina SF, O'Sullivan JP, Sharma G, Pineda Rodriguez DC, MacFadden A, Cendali F, Henen MA, Vögeli B, Kieft JS, Glasgow A, Steckelberg AL. J Mol Biol 435 168259 (2023)
  138. An RNA-Seq analysis of coronavirus in the skin of the Pangolin. Deng S, Tian X, Belshaw R, Zhou J, Zhang S, Yang Y, Huang C, Chen W, Qiu H, Choo SW. Sci Rep 14 910 (2024)
  139. An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds. Schake P, Dishnica K, Kaiser F, Leberecht C, Haupt VJ, Schroeder M. Sci Rep 13 9204 (2023)
  140. An open interface in the pre-80S ribosome coordinated by ribosome assembly factors Tsr1 and Dim1 enables temporal regulation of Fap7. Rai J, Parker MD, Huang H, Choy S, Ghalei H, Johnson MC, Karbstein K, Stroupe ME. RNA 27 221-233 (2021)
  141. An update on host immunity correlates and prospects of re-infection in COVID-19. Negi N, Maurya SP, Singh R, Das BK. Int Rev Immunol 1-26 (2021)
  142. Antibody Binding Captures High Energy State of an Antigen: The Case of Nsp1 SARS-CoV-2 as Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry. Kant R, Mishra N, Gross ML. Int J Mol Sci 24 17342 (2023)
  143. Antiviral response and immunopathogenesis of interleukin 27 in COVID-19. Valdés-López JF, Urcuqui-Inchima S. Arch Virol 168 178 (2023)
  144. Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing. Maria NI, Rapicavoli RV, Alaimo S, Bischof E, Stasuzzo A, Broek JAC, Pulvirenti A, Mishra B, Duits AJ, Ferro A, RxCOVEA Framework. Heliyon 9 e14115 (2023)
  145. Artesunate induces substantial topological alterations in the SARS-CoV-2 Nsp1 protein structure. Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM, Al-Hemaid F. J King Saud Univ Sci 101810 (2022)
  146. Bioinformatics analysis based on high-throughput sequencing data to identify hub genes related to different clinical types of COVID-19. Liu S, Long J, Liang T, Lv M, Huang X, Liang X, Su L, Zhou L. Funct Integr Genomics 23 71 (2023)
  147. COVID-19 Salivary Protein Profile: Unravelling Molecular Aspects of SARS-CoV-2 Infection. Esteves E, Mendes VM, Manadas B, Lopes R, Bernardino L, Correia MJ, Barros M, Esteves AC, Rosa N. J Clin Med 11 5571 (2022)
  148. Cap-independent translation and a precisely located RNA sequence enable SARS-CoV-2 to control host translation and escape anti-viral response. Slobodin B, Sehrawat U, Lev A, Hayat D, Zuckerman B, Fraticelli D, Ogran A, Ben-Shmuel A, Bar-David E, Levy H, Ulitsky I, Dikstein R. Nucleic Acids Res 50 8080-8092 (2022)
  149. Comparative analysis of SARS-CoV-2 variants Alpha (B.1.1.7), Gamma (P.1), Zeta (P.2) and Delta (B.1.617.2) in Vero-E6 cells: ultrastructural characterization of cytopathology and replication kinetics. Vieira DFB, Bandeira DM, da Silva MAN, de Almeida ALT, Araújo M, Machado AB, Tort LFL, Nacife VP, Siqueira MM, Motta FC, Pauvolid-Corrêa A, Barth OM. Braz J Infect Dis 28 103706 (2023)
  150. Comparison of Intracellular Transcriptional Response of NHBE Cells to Infection with SARS-CoV-2 Washington and New York Strains. Scott TM, Solis-Leal A, Lopez JB, Robison RA, Berges BK, Pickett BE. Front Cell Infect Microbiol 12 1009328 (2022)
  151. Conformational ensemble of the NSP1 CTD in SARS-CoV-2: Perspectives from the free energy landscape. Dutta P, Kshirsagar A, Bibekar P, Sengupta N. Biophys J S0006-3495(23)00102-9 (2023)
  152. Copper(II) Binding to the Intrinsically Disordered C-Terminal Peptide of SARS-CoV-2 Virulence Factor Nsp1. Morales M, Ravanfar R, Oyala PH, Gray HB, Winkler JR. Inorg Chem 61 8992-8996 (2022)
  153. Correlated sequence signatures are present within the genomic 5'UTR RNA and NSP1 protein in coronaviruses. Sosnowski P, Tidu A, Eriani G, Westhof E, Martin F. RNA 28 729-741 (2022)
  154. CryoREAD provides fully automated DNA-RNA structure modeling for cryo-EM maps. Nat Methods 20 1637-1638 (2023)
  155. DPP9 as a Potential Novel Mediator in Gastrointestinal Virus Infection. Del Castillo-Izquierdo Á, Moreno-Navarrete JM, Latorre J, Arnoriaga-Rodríguez M, Ballanti M, Monteleone G, Alessandro Paoluzi O, Mingrone G, Puig J, Ramos R, Garre-Olmo J, Jové M, Pamplona R, Portero-Otín M, Sol J, Lefebvre P, Staels B, Federici M, Fernández-Real JM, Mayneris-Perxachs J. Antioxidants (Basel) 11 2177 (2022)
  156. Development of Monoclonal Antibodies to Detect for SARS-CoV-2 Proteins. Mishra N, Teyra J, Boytz R, Miersch S, Merritt TN, Cardarelli L, Gorelik M, Mihalic F, Jemth P, Davey RA, Sidhu SS, Leung DW, Amarasinghe GK. J Mol Biol 434 167583 (2022)
  157. Diagnosing COVID-19 in human serum using Raman spectroscopy. Goulart ACC, Silveira L, Carvalho HC, Dorta CB, Pacheco MTT, Zângaro RA. Lasers Med Sci 37 2217-2226 (2022)
  158. Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53. Lee JD, Menasche BL, Mavrikaki M, Uyemura MM, Hong SM, Kozlova N, Wei J, Alfajaro MM, Filler RB, Müller A, Saxena T, Posey RR, Cheung P, Muranen T, Heng YJ, Paulo JA, Wilen CB, Slack FJ. Cell Rep 42 113478 (2023)
  159. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic. Hasankhani A, Bahrami A, Sheybani N, Aria B, Hemati B, Fatehi F, Ghaem Maghami Farahani H, Javanmard G, Rezaee M, Kastelic JP, Barkema HW. Front Immunol 12 789317 (2021)
  160. Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2. Afsar M, Narayan R, Akhtar MN, Das D, Rahil H, Nagaraj SK, Eswarappa SM, Tripathi S, Hussain T. Elife 11 e74877 (2022)
  161. Enrichment of SARS-CoV-2 Entry Factors and Interacting Intracellular Genes in Tissue and Circulating Immune Cells. Devaprasad A, Pandit A. Viruses 13 1757 (2021)
  162. Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. Tanaka T, Saito A, Suzuki T, Miyamoto Y, Takayama K, Okamoto T, Moriishi K. Antiviral Res 199 105268 (2022)
  163. Evolution of naturally arising SARS-CoV-2 defective interfering particles. Girgis S, Xu Z, Oikonomopoulos S, Fedorova AD, Tchesnokov EP, Gordon CJ, Schmeing TM, Götte M, Sonenberg N, Baranov PV, Ragoussis J, Hobman TC, Pelletier J. Commun Biol 5 1140 (2022)
  164. Fast construction of SARS-CoV-2 associated plasmid library using parallel cloning method. Meng F, Guo J, Wang S, Zhang C, Li X, Chen Y, Shi Q, Shao L, Zhang R, Wang G, Su D. Heliyon 9 e17364 (2023)
  165. Genomic Surveillance of SARS-CoV-2 Variants That Emerged in South and Southeast Asia during Early 2022. Yu Q, Tong X, Zuo L, Tao X, Xu Z, Li X, Liu H, Guan W, Liu D, Liu H, Huang F, Jia L. Viruses 15 1355 (2023)
  166. Genomic evolution of the Coronaviridae family. Zmasek CM, Lefkowitz EJ, Niewiadomska A, Scheuermann RH. Virology 570 123-133 (2022)
  167. Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon response. Lin JW, Tang C, Wei HC, Du B, Chen C, Wang M, Zhou Y, Yu MX, Cheng L, Kuivanen S, Ogando NS, Levanov L, Zhao Y, Li CL, Zhou R, Li Z, Zhang Y, Sun K, Wang C, Chen L, Xiao X, Zheng X, Chen SS, Zhou Z, Yang R, Zhang D, Xu M, Song J, Wang D, Li Y, Lei S, Zeng W, Yang Q, He P, Zhang Y, Zhou L, Cao L, Luo F, Liu H, Wang L, Ye F, Zhang M, Li M, Fan W, Li X, Li K, Ke B, Xu J, Yang H, He S, Pan M, Yan Y, Zha Y, Jiang L, Yu C, Liu Y, Xu Z, Li Q, Jiang Y, Sun J, Hong W, Wei H, Lu G, Vapalahti O, Luo Y, Wei Y, Connor T, Tan W, Snijder EJ, Smura T, Li W, Geng J, Ying B, Chen L. Cell Host Microbe (2021)
  168. How SARS-CoV-2 Alters the Regulation of Gene Expression in Infected Cells. Bignon E, Grandemange S, Dumont E, Monari A. J Phys Chem Lett 14 3199-3207 (2023)
  169. Humoral Immune Response Profile of COVID-19 Reveals Severity and Variant-Specific Epitopes: Lessons from SARS-CoV-2 Peptide Microarray. Acharjee A, Ray A, Salkar A, Bihani S, Tuckley C, Shastri J, Agrawal S, Duttagupta S, Srivastava S. Viruses 15 248 (2023)
  170. Identification of G-quadruplex DNA sequences in SARS-CoV2. Maiti AK. Immunogenetics (2022)
  171. Identification of Novel COVID-19 Biomarkers by Multiple Feature Selection Strategies. Zhang S, Qu R, Wang P, Wang S. Comput Math Methods Med 2021 2203636 (2021)
  172. Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI. Liu C, Zhang Y, Gao X, Wang G. BMC Biol 21 159 (2023)
  173. Identification of intrinsically disorder regions in non-structural proteins of SARS-CoV-2: New insights into drug and vaccine resistance. Anjum F, Mohammad T, Asrani P, Shafie A, Singh S, Yadav DK, Uversky VN, Hassan MI. Mol Cell Biochem 477 1607-1619 (2022)
  174. Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets. Mihalič F, Benz C, Kassa E, Lindqvist R, Simonetti L, Inturi R, Aronsson H, Andersson E, Chi CN, Davey NE, Överby AK, Jemth P, Ivarsson Y. Nat Commun 14 5636 (2023)
  175. Immunotoxic role of organophosphates: An unseen risk escalating SARS-CoV-2 pathogenicity. Rajak P, Ganguly A, Sarkar S, Mandi M, Dutta M, Podder S, Khatun S, Roy S. Food Chem Toxicol 149 112007 (2021)
  176. Improving SARS-CoV-2 structures: peer review by early coordinate release. Croll TI, Williams CJ, Chen VB, Richardson DC, Richardson JS. Biophys J (2021)
  177. In silico evaluation of flavonoids as potential inhibitors of SARS-CoV-2 main nonstructural proteins (Nsps)-amentoflavone as a multitarget candidate. Portilla-Martínez A, Ortiz-Flores M, Hidalgo I, Gonzalez-Ruiz C, Meaney E, Ceballos G, Nájera N. J Mol Model 28 404 (2022)
  178. In vitro reconstitution of SARS-CoV-2 Nsp1-induced mRNA cleavage reveals the key roles of the N-terminal domain of Nsp1 and the RRM domain of eIF3g. Abaeva IS, Arhab Y, Miścicka A, Hellen CUT, Pestova TV. Genes Dev 37 844-860 (2023)
  179. InfectionCMA: A Cell MicroArray Approach for Efficient Biomarker Screening in In Vitro Infection Assays. Magalhães AC, Ricardo S, Moreira AC, Nunes M, Tavares M, Pinto RJ, Gomes MS, Pereira L. Pathogens 11 313 (2022)
  180. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Hoagland DA, Møller R, Uhl SA, Oishi K, Frere J, Golynker I, Horiuchi S, Panis M, Blanco-Melo D, Sachs D, Arkun K, Lim JK, tenOever BR. Immunity (2021)
  181. Luciferase reporter assays to monitor interferon signaling modulation by SARS-CoV-2 proteins. Hirschenberger M, Hayn M, Laliberté A, Koepke L, Kirchhoff F, Sparrer KMJ. STAR Protoc 2 100781 (2021)
  182. MERS-CoV nsp1 impairs the cellular metabolic processes by selectively downregulating mRNAs in a novel granules. Pan Z, Feng Y, Wang Z, Lei Z, Han Q, Zhang J. Virulence 13 355-369 (2022)
  183. MERS-CoV nsp1 regulates autophagic flux via mTOR signalling and dysfunctional lysosomes. Feng Y, Pan Z, Wang Z, Lei Z, Yang S, Zhao H, Wang X, Yu Y, Han Q, Zhang J. Emerg Microbes Infect 11 2529-2543 (2022)
  184. Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal. Kumar P, Bhardwaj T, Giri R. RSC Adv 12 5648-5655 (2022)
  185. Molecular Insights into the Binding Behavior of Imidazolium Ionic Liquids to the Receptor Binding Domain of the SARS-CoV-2 Spike Protein. Liu P, Li Y, Liu Y, Liu J, Dong K, Jia Q. J Phys Chem B 127 4396-4405 (2023)
  186. Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients. Gratteri C, Ambrosio FA, Lupia A, Moraca F, Catalanotti B, Costa G, Bellocchi M, Carioti L, Salpini R, Ceccherini-Silberstein F, Frazia S, Malagnino V, Sarmati L, Svicher V, Bryant S, Artese A, Alcaro S. Pharmaceuticals (Basel) 16 1143 (2023)
  187. Molecular modelling and simulation techniques to investigate the effects of fungal metabolites on the SARS-CoV-2 RdRp protein inhibition. Muddapur UM, Badiger S, Shaikh IA, Ghoneim MM, Alshamrani SA, Mahnashi MH, Alsaikhan F, El-Sherbiny M, Al-Serwi RH, Khan AAL, Mannasaheb BA, Bahafi A, Iqubal SMS, Begum T, Gouse HSM, Mohammed T, Hombalimath VS. J King Saud Univ Sci 34 102147 (2022)
  188. Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity. Lupacchini L, Maggi F, Tomino C, De Dominicis C, Mollinari C, Fini M, Bonassi S, Merlo D, Russo P. Molecules 26 (2020)
  189. Non-Structural Proteins (Nsp): A Marker for Detection of Human Coronavirus Families. Tamayo-Ordóñez MC, Rosas-García NM, Ayil-Gutiérrez BA, Bello-López JM, Tamayo-Ordóñez FA, Anguebes-Franseschi F, Damas-Damas S, Tamayo-Ordóñez YJ. Pathogens 12 1185 (2023)
  190. Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Zhang K, Miorin L, Makio T, Dehghan I, Gao S, Xie Y, Zhong H, Esparza M, Kehrer T, Kumar A, Hobman TC, Ptak C, Gao B, Minna JD, Chen Z, García-Sastre A, Ren Y, Wozniak RW, Fontoura BMA. Sci Adv 7 (2021)
  191. Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells. Merino VF, Yan Y, Ordonez AA, Bullen CK, Lee A, Saeki H, Ray K, Huang T, Jain SK, Pomper MG. Antiviral Res 211 105550 (2023)
  192. Optimization of 5'UTR to evade SARS-CoV-2 Nonstructural protein 1-directed inhibition of protein synthesis in cells. Chen SC, Xu CT, Chang CF, Chao TY, Lin CC, Fu PW, Yu CH. Appl Microbiol Biotechnol 107 2451-2468 (2023)
  193. Pandemics and the English Language: Concepts Critical for Conversing About COVID-19. Greenspan NS, Pereda GA. Pathog Immun 7 78-92 (2022)
  194. Porcine Epidemic Diarrhea Virus and Its nsp14 Suppress ER Stress Induced GRP78. Zeng W, Ren J, Yang G, Jiang C, Dong L, Sun Q, Hu Y, Li W, He Q. Int J Mol Sci 24 4936 (2023)
  195. Possible Mechanism of SARS-CoV-2 Nsp1-Mediated Control of Viral Gene Expression. Zhao T, Ren Y, Wu J, Zhang Q. Front Cell Infect Microbiol 12 881749 (2022)
  196. Potential network markers and signaling pathways for B cells of COVID-19 based on single-cell condition-specific networks. Li Y, Han L, Li P, Ge J, Xue Y, Chen L. BMC Genomics 24 619 (2023)
  197. Prevention of ribosome collision-induced neuromuscular degeneration by SARS CoV-2-encoded Nsp1. Wang X, Rimal S, Tantray I, Geng J, Bhurtel S, Khaket TP, Li W, Han Z, Lu B. Proc Natl Acad Sci U S A 119 e2202322119 (2022)
  198. Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx. Vanderboom PM, Mun DG, Madugundu AK, Mangalaparthi KK, Saraswat M, Garapati K, Chakraborty R, Ebihara H, Sun J, Pandey A. Mol Cell Proteomics 20 100134 (2021)
  199. Proteomic landscape of SARS-CoV-2- and MERS-CoV-infected primary human renal epithelial cells. Kohli A, Sauerhering L, Fehling SK, Klann K, Geiger H, Becker S, Koch B, Baer PC, Strecker T, Münch C. Life Sci Alliance 5 e202201371 (2022)
  200. Proximity-dependent biotinylation detects associations between SARS coronavirus nonstructural protein 1 and stress granule-associated proteins. Gerassimovich YA, Miladinovski-Bangall SJ, Bridges KM, Boateng L, Ball LE, Valafar H, Nag A. J Biol Chem 297 101399 (2021)
  201. Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. Crozier TWM, Greenwood EJD, Williamson JC, Guo W, Porter LM, Gabaev I, Teixeira-Silva A, Grice GL, Wickenhagen A, Stanton RJ, Wang ECY, Wilson SJ, Matheson NJ, Nathan JA, McCaughan F, Lehner PJ. Wellcome Open Res 7 224 (2022)
  202. Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1. Nchioua R, Schundner A, Klute S, Koepke L, Hirschenberger M, Noettger S, Fois G, Zech F, Graf A, Krebs S, Braubach P, Blum H, Stenger S, Kmiec D, Frick M, Kirchhoff F, Sparrer KM. Life Sci Alliance 6 e202201745 (2023)
  203. SARS-CoV-2 Harnesses Host Translational Shutoff and Autophagy To Optimize Virus Yields: the Role of the Envelope (E) Protein. Waisner H, Grieshaber B, Saud R, Henke W, Stephens EB, Kalamvoki M. Microbiol Spectr 11 e0370722 (2023)
  204. SARS-CoV-2 Mutations Responsible for Immune Evasion Leading to Breakthrough Infection. Sahni C, Basu Roy Chowdhury P, Devadas D, Ashish A, Singh NK, Yadav A, Kaur M, Mishra S, Vishwakarma S, Singh R. Cureus 14 e29544 (2022)
  205. SARS-CoV-2 Non-structural protein 1(NSP1) mutation virulence and natural selection: Evolutionary trends in the six continents. Ghaleh SS, Rahimian K, Mahmanzar M, Mahdavi B, Tokhanbigli S, Sisakht MM, Farhadi A, Bakhtiari MM, Kuehu DL, Deng Y. Virus Res 323 199016 (2022)
  206. SARS-CoV-2 Nsp1 mediated mRNA degradation requires mRNA interaction with the ribosome. Shehata SI, Parker R. RNA Biol 20 444-456 (2023)
  207. SARS-CoV-2 Nsp2 Contributes to Inflammation by Activating NF-κB. Lacasse É, Gudimard L, Dubuc I, Gravel A, Allaeys I, Boilard É, Flamand L. Viruses 15 334 (2023)
  208. SARS-CoV-2 Nsp8 suppresses MDA5 antiviral immune responses by impairing TRIM4-mediated K63-linked polyubiquitination. Zhang X, Yang Z, Pan T, Sun Q, Chen Q, Wang PH, Li X, Kuang E. PLoS Pathog 19 e1011792 (2023)
  209. SARS-CoV-2 ORF6 protein targets TRIM25 for proteasomal degradation to diminish K63-linked RIG-I ubiquitination and type-I interferon induction. Khatun O, Sharma M, Narayan R, Tripathi S. Cell Mol Life Sci 80 364 (2023)
  210. SARS-CoV-2 and Glutamine: SARS-CoV-2 Triggered Pathogenesis via Metabolic Reprograming of Glutamine in Host Cells. Bharadwaj S, Singh M, Kirtipal N, Kang SG. Front Mol Biosci 7 627842 (2020)
  211. SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation. Xu Z, Choi JH, Dai DL, Luo J, Ladak RJ, Li Q, Wang Y, Zhang C, Wiebe S, Liu ACH, Ran X, Yang J, Naeli P, Garzia A, Zhou L, Mahmood N, Deng Q, Elaish M, Lin R, Mahal LK, Hobman TC, Pelletier J, Alain T, Vidal SM, Duchaine T, Mazhab-Jafari MT, Mao X, Jafarnejad SM, Sonenberg N. Proc Natl Acad Sci U S A 119 e2204539119 (2022)
  212. SARS-CoV-2 infection engenders heterogeneous ribonucleoprotein interactions to impede translation elongation in the lungs. Kim J, Youn D, Choi S, Lee YW, Sumberzul D, Yoon J, Lee H, Bae JW, Noh H, On D, Hong SM, An SH, Jang HJ, Kim SY, Kim YB, Hwang JY, Lee HJ, Bin Kim H, Park JW, Yun JW, Shin JS, Seo JY, Nam KT, Choi KS, Lee HY, Chang H, Seong JK, Cho J. Exp Mol Med (2023)
  213. SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways. Verma AK, Zheng J, Meyerholz DK, Perlman S. JCI Insight 7 e160277 (2022)
  214. SARS-CoV-2 modulation of RIG-I-MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches. Wang M, Zhao Y, Liu J, Li T. MedComm Futur Med 1 e29 (2022)
  215. SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV Ortholog. Chen J, Li Z, Guo J, Xu S, Zhou J, Chen Q, Tong X, Wang D, Peng G, Fang L, Xiao S. J Virol 96 e0003722 (2022)
  216. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells. Gori Savellini G, Anichini G, Cusi MG. Virus Res 332 199134 (2023)
  217. SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms. O'Donoghue SI, Schafferhans A, Sikta N, Stolte C, Kaur S, Ho BK, Anderson S, Procter JB, Dallago C, Bordin N, Adcock M, Rost B. Mol Syst Biol 17 e10079 (2021)
  218. SARS-CoV-2 uses CD4 to infect T helper lymphocytes. Brunetti NS, Davanzo GG, de Moraes D, Ferrari AJR, Souza GF, Muraro SP, Knittel TL, Boldrini VO, Monteiro LB, Virgílio-da-Silva JV, Profeta GS, Wassano NS, Nunes Santos L, Carregari VC, Dias AHS, Veras FP, Tavares LA, Forato J, Castro IMS, Silva-Costa LC, Palma AC, Mansour E, Ulaf RG, Bernardes AF, Nunes TA, Ribeiro LC, Agrela MV, Moretti ML, Buscaratti LI, Crunfli F, Ludwig RG, Gerhardt JA, Munhoz-Alves N, Marques AM, Sesti-Costa R, Amorim MR, Toledo-Teixeira DA, Parise PL, Martini MC, Bispos-Dos-Santos K, Simeoni CL, Granja F, Silvestrini VC, de Oliveira EB, Faca VM, Carvalho M, Castelucci BG, Pereira AB, Coimbra LD, Dias MMG, Rodrigues PB, Gomes ABSP, Pereira FB, Santos LMB, Bloyet LM, Stumpf S, Pontelli MC, Whelan S, Sposito AC, Carvalho RF, Vieira AS, Vinolo MAR, Damasio A, Velloso L, Figueira ACM, da Silva LLP, Cunha TM, Nakaya HI, Marques-Souza H, Marques RE, Martins-de-Souza D, Skaf MS, Proenca-Modena JL, Moraes-Vieira PMM, Mori MA, Farias AS. Elife 12 e84790 (2023)
  219. SARS-CoV-2 variant-specific differences in inhibiting the effects of the PKR-activated integrated stress response. Christ W, Klingström J, Tynell J. Virus Res 339 199271 (2024)
  220. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Bouhaddou M, Reuschl AK, Polacco BJ, Thorne LG, Ummadi MR, Ye C, Rosales R, Pelin A, Batra J, Jang GM, Xu J, Moen JM, Richards AL, Zhou Y, Harjai B, Stevenson E, Rojc A, Ragazzini R, Whelan MVX, Furnon W, De Lorenzo G, Cowton V, Syed AM, Ciling A, Deutsch N, Pirak D, Dowgier G, Mesner D, Turner JL, McGovern BL, Rodriguez ML, Leiva-Rebollo R, Dunham AS, Zhong X, Eckhardt M, Fossati A, Liotta NF, Kehrer T, Cupic A, Rutkowska M, Mena I, Aslam S, Hoffert A, Foussard H, Olwal CO, Huang W, Zwaka T, Pham J, Lyons M, Donohue L, Griffin A, Nugent R, Holden K, Deans R, Aviles P, Lopez-Martin JA, Jimeno JM, Obernier K, Fabius JM, Soucheray M, Hüttenhain R, Jungreis I, Kellis M, Echeverria I, Verba K, Bonfanti P, Beltrao P, Sharan R, Doudna JA, Martinez-Sobrido L, Patel AH, Palmarini M, Miorin L, White K, Swaney DL, Garcia-Sastre A, Jolly C, Zuliani-Alvarez L, Towers GJ, Krogan NJ. Cell 186 4597-4614.e26 (2023)
  221. SARS-CoV-2 viral protein Nsp2 stimulates translation under normal and hypoxic conditions. Korneeva N, Khalil MI, Ghosh I, Fan R, Arnold T, De Benedetti A. Virol J 20 55 (2023)
  222. SARS-CoV-2: analysis of the effects of mutations in non-structural proteins. Senthilazhagan K, Sakthimani S, Kallanja D, Venkataraman S. Arch Virol 168 186 (2023)
  223. Selective translational control of cellular and viral mRNAs by RPS3 mRNA binding. Havkin-Solomon T, Itzhaki E, Joffe N, Reuven N, Shaul Y, Dikstein R. Nucleic Acids Res 51 4208-4222 (2023)
  224. Serial co-expression analysis of host factors from SARS-CoV viruses highly converges with former high-throughput screenings and proposes key regulators. Pérez-Pulido AJ, Asencio-Cortés G, Brokate-Llanos AM, Brea-Calvo G, Rodríguez-Griñolo R, Garzón A, Muñoz MJ. Brief Bioinform 22 1038-1052 (2021)
  225. Single-cell RNA-sequencing data analysis reveals a highly correlated triphasic transcriptional response to SARS-CoV-2 infection. Gutiérrez PA, Elena SF. Commun Biol 5 1302 (2022)
  226. Site-specific recognition of SARS-CoV-2 nsp1 protein with a tailored titanium dioxide nanoparticle - elucidation of the complex structure using NMR data and theoretical calculation. Agback P, Agback T, Dominguez F, Frolova EI, Seisenbaeva GA, Kessler VG. Nanoscale Adv 4 1527-1532 (2022)
  227. Special Features of COVID-19 in the FMODB: Fragment Molecular Orbital Calculations and Interaction Energy Analysis of SARS-CoV-2-Related Proteins. Fukuzawa K, Kato K, Watanabe C, Kawashima Y, Handa Y, Yamamoto A, Watanabe K, Ohyama T, Kamisaka K, Takaya D, Honma T. J Chem Inf Model 61 4594-4612 (2021)
  228. Stability of SARS-CoV-2-Encoded Proteins and Their Antibody Levels Correlate with Interleukin 6 in COVID-19 Patients. Li W, Kitsios GD, Bain W, Wang C, Li T, Fanning KV, Deshpande R, Qin X, Morris A, Lee JS, Zou C. mSystems 7 e0005822 (2022)
  229. Structural analysis of SARS-Cov-2 nonstructural protein 1 polymorphisms found in the Brazilian Amazon. Zanchi FB, Mariúba LA, Nascimento V, Souza V, Corado A, Nascimento F, Costa ÁK, Duarte D, Silva G, Mejía M, Pessoa K, Gonçalves L, Brandão MJ, Jesus M, Glória J, Silva M, Mattos T, da Costa C, Naveca FG. Exp Biol Med (Maywood) 246 2332-2337 (2021)
  230. Structure of Nonstructural Protein 1 from SARS-CoV-2. Clark LK, Green TJ, Petit CM. J Virol 95 (2021)
  231. Structure of the SARS-CoV-2 Nsp1/5'-Untranslated Region Complex and Implications for Potential Therapeutic Targets, a Vaccine, and Virulence. Vankadari N, Jeyasankar NN, Lopes WJ. J Phys Chem Lett 11 9659-9668 (2020)
  232. Suppression and Activation of Intracellular Immune Response in Initial Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Jia L, Chen Z, Zhang Y, Ma L, Wang L, Hu X, Liu H, Chen J, Liu D, Guan W. Front Microbiol 12 768740 (2021)
  233. Systematic Exploration of SARS-CoV-2 Adaptation to Vero E6, Vero E6/TMPRSS2, and Calu-3 Cells. Aiewsakun P, Phumiphanjarphak W, Ludowyke N, Purwono PB, Manopwisedjaroen S, Srisaowakarn C, Ekronarongchai S, Suksatu A, Yuvaniyama J, Thitithanyanont A. Genome Biol Evol 15 evad035 (2023)
  234. article-commentary Taking on SARS-CoV-2. Kučan Brlić P, Brizić I. Elife 11 e80552 (2022)
  235. The Omicron Sub-Variant BA.4 Displays a Remarkable Lack of Clinical Signs in a Golden Syrian Hamster Model of SARS-CoV-2 Infection. Davies ER, Ryan KA, Bewley KR, Coombes NS, Salguero FJ, Carnell OT, Biddlecombe S, Charlton M, Challis A, Cross ES, Handley A, Ngabo D, Weldon TM, Hall Y, Funnell SGP. Viruses 15 1133 (2023)
  236. The Potential of Eukaryotic Cell-Free Systems as a Rapid Response to Novel Zoonotic Pathogens: Analysis of SARS-CoV-2 Viral Proteins. Ramm F, Dondapati SK, Trinh HA, Wenzel D, Walter RM, Zemella A, Kubick S. Front Bioeng Biotechnol 10 896751 (2022)
  237. The flexible N-terminal motif of uL11 unique to eukaryotic ribosomes interacts with P-complex and facilitates protein translation. Yang L, Lee KM, Yu CW, Imai H, Choi AK, Banfield DK, Ito K, Uchiumi T, Wong KB. Nucleic Acids Res 50 5335-5348 (2022)
  238. The severe acute respiratory syndrome coronavirus 2 non-structural proteins 1 and 15 proteins mediate antiviral immune evasion. Boodhoo N, Matsuyama-Kato A, Shojadoost B, Behboudi S, Sharif S. Curr Res Virol Sci 3 100021 (2022)
  239. The two-stage molecular scenery of SARS-CoV-2 infection with implications to disease severity: An in-silico quest. Potamias G, Gkoublia P, Kanterakis A. Front Immunol 14 1251067 (2023)
  240. Transcriptional Profiling of SARS-CoV-2-Infected Calu-3 Cells Reveals Immune-Related Signaling Pathways. Pereira EPV, da Silva Felipe SM, de Freitas RM, da Cruz Freire JE, Oliveira AER, Canabrava N, Soares PM, van Tilburg MF, Guedes MIF, Grueter CE, Ceccatto VM. Pathogens 12 1373 (2023)
  241. Translation of SARS-CoV-2 gRNA Is Extremely Efficient and Competitive despite a High Degree of Secondary Structures and the Presence of an uORF. Condé L, Allatif O, Ohlmann T, de Breyne S. Viruses 14 1505 (2022)
  242. Understanding COVID-19 Pathogenesis: A Drug-Repurposing Effort to Disrupt Nsp-1 Binding to Export Machinery Receptor Complex. Vasudevan S, Baraniuk JN. Pathogens 10 1634 (2021)
  243. Universal features of Nsp1-mediated translational shutdown by coronaviruses. Schubert K, Karousis ED, Ban I, Lapointe CP, Leibundgut M, Bäumlin E, Kummerant E, Scaiola A, Schönhut T, Ziegelmüller J, Puglisi JD, Mühlemann O, Ban N. Mol Cell 83 3546-3557.e8 (2023)
  244. Using deep-learning predictions of inter-residue distances for model validation. Sánchez Rodríguez F, Chojnowski G, Keegan RM, Rigden DJ. Acta Crystallogr D Struct Biol 78 1412-1427 (2022)
  245. Viral RNA Is a Hub for Critical Host-Virus Interactions. Castello A, Iselin L. Subcell Biochem 106 365-385 (2023)


Quick links